US20230073725A1 - Metabolite biomarker profile and method of use to diagnose pulmonary arterial hypertension (pah) - Google Patents
Metabolite biomarker profile and method of use to diagnose pulmonary arterial hypertension (pah) Download PDFInfo
- Publication number
- US20230073725A1 US20230073725A1 US17/792,902 US202117792902A US2023073725A1 US 20230073725 A1 US20230073725 A1 US 20230073725A1 US 202117792902 A US202117792902 A US 202117792902A US 2023073725 A1 US2023073725 A1 US 2023073725A1
- Authority
- US
- United States
- Prior art keywords
- acid
- pah
- disease
- subject
- panel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims abstract description 210
- 239000002207 metabolite Substances 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 79
- 239000000090 biomarker Substances 0.000 title claims abstract description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 108
- 201000010099 disease Diseases 0.000 claims abstract description 97
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 74
- 208000019622 heart disease Diseases 0.000 claims abstract description 51
- 208000024891 symptom Diseases 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract description 25
- 238000003745 diagnosis Methods 0.000 claims abstract description 20
- 210000002700 urine Anatomy 0.000 claims abstract description 9
- 230000002503 metabolic effect Effects 0.000 claims description 82
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 67
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 57
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 40
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 39
- 239000012472 biological sample Substances 0.000 claims description 32
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 28
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 28
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 26
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 claims description 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 26
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 26
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 24
- 229960000367 inositol Drugs 0.000 claims description 23
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 23
- 235000006408 oxalic acid Nutrition 0.000 claims description 22
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 claims description 20
- DZAIOXUZHHTJKN-UHFFFAOYSA-N 3,4-dihydroxybutyric acid Chemical compound OCC(O)CC(O)=O DZAIOXUZHHTJKN-UHFFFAOYSA-N 0.000 claims description 20
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 20
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 20
- 239000004386 Erythritol Substances 0.000 claims description 20
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 20
- JRLGPAXAGHMNOL-LURJTMIESA-N N(2)-acetyl-L-ornithine Chemical compound CC(=O)N[C@H](C([O-])=O)CCC[NH3+] JRLGPAXAGHMNOL-LURJTMIESA-N 0.000 claims description 20
- 229930185560 Pseudouridine Natural products 0.000 claims description 20
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 20
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 20
- 229940091181 aconitic acid Drugs 0.000 claims description 20
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 claims description 20
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 20
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 claims description 20
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 20
- 229940009714 erythritol Drugs 0.000 claims description 20
- 235000019414 erythritol Nutrition 0.000 claims description 20
- 239000001530 fumaric acid Substances 0.000 claims description 20
- 239000000174 gluconic acid Substances 0.000 claims description 20
- 235000012208 gluconic acid Nutrition 0.000 claims description 20
- 235000013922 glutamic acid Nutrition 0.000 claims description 20
- 239000004220 glutamic acid Substances 0.000 claims description 20
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 20
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 claims description 20
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 20
- 229940116269 uric acid Drugs 0.000 claims description 20
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims description 19
- 229910019142 PO4 Inorganic materials 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 19
- 229940097043 glucuronic acid Drugs 0.000 claims description 19
- 239000010452 phosphate Substances 0.000 claims description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 19
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims description 18
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 18
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 claims description 18
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 18
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 18
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 18
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 18
- 238000010801 machine learning Methods 0.000 claims description 18
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 claims description 14
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 claims description 14
- 229940109239 creatinine Drugs 0.000 claims description 14
- HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 claims description 14
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 claims description 13
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 claims description 13
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 13
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 13
- QXKAIJAYHKCRRA-BXXZVTAOSA-N D-ribonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-BXXZVTAOSA-N 0.000 claims description 13
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 claims description 13
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000004471 Glycine Substances 0.000 claims description 13
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 13
- 239000004472 Lysine Substances 0.000 claims description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 13
- 239000004202 carbamide Substances 0.000 claims description 13
- -1 focuse Chemical compound 0.000 claims description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 13
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 13
- 229940055726 pantothenic acid Drugs 0.000 claims description 13
- 235000019161 pantothenic acid Nutrition 0.000 claims description 13
- 239000011713 pantothenic acid Substances 0.000 claims description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 13
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 12
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 claims description 12
- 229960002989 glutamic acid Drugs 0.000 claims description 12
- 229960002449 glycine Drugs 0.000 claims description 12
- JBOPQACSHPPKEP-UHFFFAOYSA-N indoxyl acetate Natural products C1=CC=C2C(OC(=O)C)=CNC2=C1 JBOPQACSHPPKEP-UHFFFAOYSA-N 0.000 claims description 12
- 238000007726 management method Methods 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 claims description 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 9
- VOXXWSYKYCBWHO-UHFFFAOYSA-N 3-phenyllactic acid Chemical compound OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 claims description 9
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 claims description 9
- 229940097276 5-methoxytryptamine Drugs 0.000 claims description 9
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 9
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- 239000001361 adipic acid Substances 0.000 claims description 9
- 235000011037 adipic acid Nutrition 0.000 claims description 9
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 claims description 9
- 235000003704 aspartic acid Nutrition 0.000 claims description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 claims description 9
- 230000002596 correlated effect Effects 0.000 claims description 9
- 229960003067 cystine Drugs 0.000 claims description 9
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 9
- 235000011180 diphosphates Nutrition 0.000 claims description 9
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 9
- 229950010772 glucose-1-phosphate Drugs 0.000 claims description 9
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 claims description 9
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 claims description 9
- 229960005261 aspartic acid Drugs 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 8
- 238000012549 training Methods 0.000 claims description 8
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 238000001311 chemical methods and process Methods 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000003442 weekly effect Effects 0.000 claims description 5
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 4
- 229960002598 fumaric acid Drugs 0.000 claims description 3
- 229950006191 gluconic acid Drugs 0.000 claims description 3
- 238000007477 logistic regression Methods 0.000 claims description 3
- 238000002705 metabolomic analysis Methods 0.000 abstract description 12
- 230000001431 metabolomic effect Effects 0.000 abstract description 11
- 238000012216 screening Methods 0.000 abstract description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 5
- 208000020193 Pulmonary artery hypoplasia Diseases 0.000 abstract 5
- 230000015654 memory Effects 0.000 description 18
- 238000004590 computer program Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 11
- 206010033557 Palpitations Diseases 0.000 description 10
- 238000001457 gas chromatography time-of-flight mass spectrometry Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 9
- 208000019693 Lung disease Diseases 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 238000000513 principal component analysis Methods 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 6
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 208000013220 shortness of breath Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000013399 early diagnosis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 210000001147 pulmonary artery Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 150000003628 tricarboxylic acids Chemical class 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000004066 metabolic change Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000037905 systemic hypertension Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000013135 deep learning Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021072 Pulmonary hypertension owing to lung disease and/or hypoxia Diseases 0.000 description 1
- 208000021085 Pulmonary hypertension with unclear multifactorial mechanism Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000010729 leg swelling Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- Pulmonary arterial hypertension a condition in which elevated pressure is found in the pulmonary artery, is an incurable, progressive disorder, and early diagnosis and treatment of PAH are associated with increased survival.
- PAH Pulmonary arterial hypertension
- DM type 2 Diabetes Mellitus
- PAH diagnosis due to the asymptomatic nature of PAH development as well as PAH's symptomatic similarity to hypertension from metabolic disorders (e.g., type 2 Diabetes Mellitus, DM) or left heart disease, there are severe delays in PAH diagnosis.
- therapy starts only at an advanced stage of the disease and if it is not successfully treated, it can lead to right ventricular hypertrophy and right-sided heart failure.
- there is a critical need to improve diagnostic approaches for diagnosis of PAH in its early stages and differentiation of similar pathologies.
- the present invention relates to diagnosing and monitoring PAH in a patient.
- the present invention features an in vitro diagnostic (IVD) tool comprising a metabolomic biomarker panel representing a profile or fingerprint and methods of using the profile or fingerprint for diagnosing and monitoring PAH; the profile comprises a unique panel of 36 biomarkers (e.g., a fingerprint) that can be detected in easily obtained specimens from a patient, for example, plasma, serum and/or urine.
- IVD in vitro diagnostic
- the present invention assesses a profile of circulating metabolites that uniquely allows the identification of patients with PAH at an early stage of disease, before the condition has progressed sufficiently to produce clinical symptoms.
- the profile or fingerprint distinguishes PAH from hypertension due to type 2 Diabetes Mellitus (DM) and left heart disease.
- the present invention features a set of metabolites for early diagnosis of PAH comprising—oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, uridine diphosphate (UDP)-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline
- Pulmonary arterial hypertension induces a distinct signature of circulating metabolites.
- Several previous reports were focused on the metabolic profiling of plasma and lung samples from pre-clinical models and patients. However, these prior comparisons were derived from healthy controls as described herein. It is more important to identify the markers that distinct PAH from other pathologies, which may show alterations of similar metabolites described herein. Metabolic reprogramming and a significant component of cardiac changes in PAH could mask PAH among more abundant conditions, such as metabolic disorders or left heart diseases.
- the present invention differentiates the plasma metabolic profiles of patients with idiopathic PAH, patients with type 2 diabetes mellitus (DM) and patients with left heart diseases (Heart).
- idiopathic pulmonary arterial hypertension are particularly likely to be diagnosed at a late stage of the disease because the symptoms are nonspecific; diagnosis requires complex or invasive tests. This has increased the need for better diagnostic tools.
- Biomarkers specifically indicating disease, disease stage, and treatment response to a particular treatment are ideal tools for optimization of pulmonary hypertension management.
- monitoring of pulmonary hypertension via biomarkers is important to better determine the urgency of lung transplantation in patients with diseases that are difficult to treat.
- the present invention uses targeted metabolomics to quantify primary plasma metabolites or biomarkers, including carbohydrates, amino acids, and nucleotides for example by GC-TOF mass spectrometry.
- the present invention shows that the plasma metabolomics profile is distinctly different in patients with PAH compared to diabetic patients or patients with left heart diseases. Therefore, the unique plasma metabolome described herein has a strong potential to serve as a diagnostic tool.
- the present invention shows that 36 unique metabolites are significantly altered in PAH patients compared to either diabetics or left heart patients or healthy people (Table 1) and could be used as a fingerprint for PAH. These unique metabolites can be classified into a few major groups comprising mitochondrial-derived metabolites, carbohydrates, myo-inositol and its derivatives, and metabolites that are indicative of damage known to be directly associated with PAH or an altered gut microbiome. Of these 36 metabolites, a minimum of 5 metabolites are critical for diagnosis of PAH and to differentiate PAH from DM or left heart disease.
- Metabolites that are significantly different in PAH cohort vs. heart or DM cohorts (a minimum of five (5) metabolites critical for the diagnosis for PAH and to differentiate PAH from DM or left heart disease).
- a fold change less than 1.0 in the healthy control indicates that the metabolite is decreased in PAH compared to the compared cohort.
- a fold change greater than 1.0 in the healthy control indicates that the metabolite is increased in PAH compared to the compared cohort.
- the present invention shows the value of metabolic profiling as a new diagnostic tool and provides subsequent research with a specific set of preselected metabolites that could serve as a fingerprint of PAH.
- the present invention also highlights the potential value of the particular metabolites in dissecting the pathogenesis of PAH.
- One of the unique and inventive technical features of the present invention is using a profile or panel (fingerprint) of 5 out of 36 metabolites for early diagnosis of PAH. Without wishing to limit the invention to any theory or mechanism, it is believed that the technical feature of the present invention advantageously provides for differentiating PAH from DM and/or left heart disease. None of the presently known prior references or work has the unique inventive technical feature of the present invention.
- metabolites described herein are also present and/or altered in similar PH pathologies from metabolic disorders (e.g., DM; left heart disease) and it would be counterintuitive or not obvious that these select metabolites can differentiate PAH from DM and/or left heart disease.
- metabolic disorders e.g., DM; left heart disease
- the inventive technical feature of the present invention contributed to a surprising result.
- the inventors of the present invention surprisingly found that the determination of the level of five or more of the aforementioned 36 metabolites of a patient-derived biological sample enables diagnosis of PAH and differentiation from DM and left heart disease even though these metabolites are also altered in DM and left heart disease.
- the present invention features a computer-implemented method for diagnosing a subject with a disease.
- the method comprises inputting expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject.
- the method comprises determining whether expression of the metabolic biomarkers in the biological sample obtained from the subject is indicative of a disease using a computer system programmed with a trained machine learning classifier for distinguishing subjects with different diseases and without disease.
- the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having disease and from control subjects that do not have disease.
- the method comprises diagnosing the subject.
- the expression data of the panel of metabolic biomarkers in the biological sample obtained from the subject is correlated by the computer system to be indicative of disease; and where the diagnostic accuracy is at least 90%.
- the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, ly
- the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid
- the present invention may further feature a method of treating a subject with pulmonary arterial hypertension (PAH).
- PAH pulmonary arterial hypertension
- the method comprises determining the expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject.
- the method comprises treating PAH in a subject identified as having differing levels of the panel of metabolic biomarkers when compared to the levels of said metabolic biomarkers in a normal subject.
- the panel of metabolic biomarkers comprises oxalic acid, aminomalonate, pseudouridine, gluconic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid, glutamic acid, phosphate, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- the subject with PAH has a higher level of oxalic acid, aminomalonate, pseudouridine, gluconic acid, uric acid, UDP-glucuronic acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid. glutamic acid. N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, oxoproline than the normal subject.
- the subject with PAH has a lower level of erythritol, fumaric acid, and phosphate than the normal subject.
- the present invention may feature a non-transitory, computer-readable medium having computer executable instructions for causing a processor to execute a method for diagnosing a subject with a disease.
- the method comprises determining whether expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is indicative of the disease using a trained machine learning classifier for distinguishing subjects with different diseases and without disease.
- the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having the disease and from control subjects that do not have disease.
- the method comprises diagnosing the subject if the expression data is correlated to be indicative of the disease. In some embodiments, the diagnostic accuracy is at least 90%.
- the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- oxalic acid
- the present invention may also feature a kit for diagnosing a subject with a disease.
- the kit comprises one or more reference metabolic biomarker panels (see Table 1, 2, 3).
- the kit comprises a non-transitory, computer-readable medium described herein.
- expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is inputted into a computer that executes the computer executable instructions of the non-transitory, computer-readable medium.
- a subject is diagnosed with disease when the expression data of the panel of metabolic biomarkers in the biological subject is correlated with the one or more reference metabolic biomarker panels by the computer to be indicative of disease and where the diagnostic accuracy is at least 90%.
- the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- oxalic acid amino
- the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- FIG. 1 A shows heat maps and
- FIG. 1 B shows principal component analysis (PCA) showing the clustering of the PAH group that could differentiate PAH patients from DM and Heart by circulating metabolites.
- PCA principal component analysis
- FIG. 3 shows circulating metabolites distinguish PAH patients from other diseases.
- FIG. 3 shows principal component analysis (PCA) of Health and PAH cohorts.
- PCA principal component analysis
- Profiling of circulating metabolites was focused on eleven metabolites that significantly distinguish PAH patients from the healthy subjects. Ellipses indicate 95% confidence.
- Panel #1 metabolites Table 1
- healthy individuals are efficiently separated from PAH patients ( FIG. 3 ).
- Ellipses show 95% confidence that the next examined person will fall inside the ellipse corresponding to the diagnosis.
- the PAH cohort consisted of two geographical locations (the University of Colorado and University of Arizona cohorts), which confirm that patients' geographical affiliation does not affect the test outcome
- FIG. 4 shows early PAH detection using Panel #1 (Table 1).
- FIG. 4 shows a PCA in which there is an overlap between the mild PAH (mPAP 20-25 mmHg, diamonds), advanced PAH (mPAP>45 mmHg, cicles), and treatment na ⁇ ve group (triangles). This result indicates that metabolically all groups are similar and could be efficiently identified regardless of the disease stage or treatment approach.
- FIG. 5 A- 5 B shows that machine learning/deep learning (ML/DL) algorithms can be used for metabolic pattern recognition.
- Machine learning algorithms are robust tools for recognizing a variety of patterns, including metabolic panels.
- Panel #1 was used for the logistic regression algorithm training. After training, the algorithm randomly picked a sample and marked it as unknown (cross-validation), and predicted the disease.
- the confusion matrix shown in FIG. 5 A indicates ML predictions for PAH patients vs. Healthy controls indication—100% accuracy.
- FIG. 5 B shows the confusion matrix for predicting diabetics (d), left heart disease (h), and pulmonary hypertension (p), and ⁇ - indicates the number of “unknown samples” attempts. Based on these data, the ML/DL approach shows no confusion in diagnosing PAH patients using panels of circulating metabolites.
- pulmonary hypertension refers to a disease characterized by an increase of blood pressure in the pulmonary artery. Pulmonary hypertension is determined as mean pulmonary artery pressure (mPAP) 20 mm Hg at rest measured by right heart catheterization. The increase in pulmonary arterial blood pressure may lead to shortness of breath, dizziness, fainting, leg swelling, and other symptoms. Pulmonary hypertension can be a severe disease with a markedly decreased exercise tolerance. The disease may be hereditary. According to the most recent classification of the World Health Organization (WHO), pulmonary hypertension can be one of the following different types: pulmonary arterial hypertension (PAH), pulmonary hypertension due to left heart disease, pulmonary hypertension due to lung disease and/or hypoxia (e. g.
- PAH pulmonary arterial hypertension
- pulmonary hypertension due to left heart disease pulmonary hypertension due to lung disease and/or hypoxia
- PH pulmonary hypertension due to chronic obstructive pulmonary disease (COPD) or PH due to interstitial lung disease (ILD), chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary hypertension with unclear multifactorial mechanisms (group 5).
- COPD chronic obstructive pulmonary disease
- ILD interstitial lung disease
- CTEPH chronic thromboembolic pulmonary hypertension
- group 5 pulmonary hypertension with unclear multifactorial mechanisms
- pulmonary arterial hypertension refers to a disease characterized by an increase of blood pressure in the pulmonary artery where underlying causes for example left heart disease, lung disease, CTEPH, and group 5 diseases have been excluded.
- Pulmonary arterial hypertension includes a number of subgroups. In particular, it encompasses idiopathic pulmonary arterial hypertension (IPAH), hereditary PAH, and associated PAH (APAH) which may be associated to drug or toxins, connective tissue diseases, HIV infection, portal hypertension.
- IIPAH idiopathic pulmonary arterial hypertension
- APAH associated PAH
- PAH and PH may be used interchangeably.
- administering refers to the act of physically delivering a composition or other therapy (e.g. a treatment for PAH) described herein into a subject by such routes as oral, mucosal, topical, transdermal, suppository, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration.
- Parenteral administration includes intravenous, intramuscular, intra-arterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration.
- a subject can be an animal (amphibian, reptile, avian, fish, or mammal) such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) or a primate (e.g., monkey, ape and human).
- a non-primate e.g., cows, pigs, horses, cats, dogs, rats, etc.
- a primate e.g., monkey, ape and human
- the subject is a human.
- the subject is a mammal (e.g., a human, a dog) having a disease, disorder or condition described herein.
- the subject is a mammal (e.g., a human, a dog) at risk of developing a disease, disorder or condition described herein.
- a mammal e.g., a human, a dog
- the term patient refers to a human under medical care or animals under veterinary care.
- normal subject or “healthy subject” or “control subject” may be used interchangeably and refers to a subject with no underlying chronic or acute disease conditions.
- treating refers to any indicia of success or amelioration of the progression, severity, and/or duration of a disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a patient's physical or mental well-being.
- Common treatments for PAH comprise administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and/or balloon angioplasty.
- ⁇ ективное amount refers to the amount of a therapy or medication (e.g., treatment for PAH) which is sufficient to reduce and/or ameliorate the severity and/or duration of a given disease, disorder or condition and/or a symptom related thereto. This term also encompasses an amount necessary for the reduction or amelioration of the advancement or progression of a given disease (e.g., PAH), disorder or condition, reduction or amelioration of the recurrence, development or onset of a given disease, disorder or condition, and/or to improve or enhance the prophylactic or therapeutic effect(s) of another therapy. In some embodiments, “effective amount” as used herein also refers to the amount of therapy provided herein to achieve a specified result.
- a therapy or medication e.g., treatment for PAH
- the term “therapeutically effective amount” of a drug or intervention is an amount sufficient enough to provide a therapeutic benefit in the treatment or management of a PAH, or to delay or minimize one or more symptoms associated with the presence of PAH.
- a therapeutically effective amount of a treatment for PAH means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of PAH.
- the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of PAH, or enhances the therapeutic efficacy of another therapeutic agent.
- a therapy is any protocol, method and/or agent that can be used in the prevention, management, treatment and/or amelioration of a given disease, disorder or condition.
- the terms “therapies” and “therapy” refer to a drug therapy, biological therapy, supportive therapy, radiation therapy, exercise therapy, and/or other therapies useful in the prevention, management, treatment and/or amelioration of a given disease, disorder or condition known to one of skill in the art such as medical personnel.
- Common therapies for PAH comprise administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and/or balloon angioplasty.
- the present invention features diagnostic, treatment and monitoring methods, and kits for PAH that allow for early diagnosis as well as monitoring of PAH and distinction of PAH from DM and/or left heart disease.
- the present invention utilizes targeted metabolomics to determine levels of metabolites, which are measured in a biological sample (e.g., plasma, urine, serum) using standard analytical techniques including GC-TOF mass spectrometry.
- the metabolites comprise oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, uridine diphosphate (UDP)-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- UDP uridine diphosphate
- the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- a metabolic profile is then determined based on the measured level of at least one metabolite.
- the profile is a metabolic fingerprint that distinguishes patients with PAH as compared to those with DM and/or left heart disease. This fingerprint can be used for diagnosis, monitoring, guiding treatment for patients having or suspected of having PAH.
- the present invention features a computer-implemented method for diagnosing a subject with a disease.
- the method comprises inputting expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject.
- the method comprises determining whether expression of the metabolic biomarkers in the biological sample obtained from the subject is indicative of a disease using a computer system programmed with a trained machine learning classifier for distinguishing subjects with different diseases and without disease.
- the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having disease and from control subjects that do not have disease.
- the method comprises diagnosing the subject.
- the expression data of the panel of metabolic biomarkers in the biological sample obtained from the subject is correlated by the computer system to be indicative of disease; and where the diagnostic accuracy is at least 90%.
- the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, ly
- the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- the expression data of the panel of metabolic biomarkers is determined using standard clinical chemistry techniques, protein analytic techniques, nucleic acid techniques, and/or analytical techniques suitable for metabolite analysis (e.g., Gas chromatography—time of flight mass spectrometry (GC-TOF) mass spectrometry, liquid chromatography mass spectrometry (LCMS), Nuclear magnetic resonance (NMR)).
- GC-TOF Gas chromatography—time of flight mass spectrometry
- LCMS liquid chromatography mass spectrometry
- NMR Nuclear magnetic resonance
- the trained machine learning classifiers are the machine learning/deep learning algorithms including logistic regression, neural network, and other algorithms.
- a machine learning classifier utilizes some training data to train algorithms to predict the class (a disease) with given input variables (expression data of metabolic biomarkers).
- the present invention may include a processor in communication with various elements of hardware.
- the processor includes one or more processors configured to implement a set of instructions corresponding to any of the methods disclosed herein.
- the processor can be configured to implement a set of instructions (stored in memory of hardware or sub-system) to provide a correlation between the expression data and a particular disease.
- a sub-system can include hardware and software capable of facilitating the processing of data generated by hardware, in conjunction with, or as a substitute for, the processing that is normally handled by the processor.
- the diagnostic accuracy of the computer system is 100%. In some embodiments, the diagnostic accuracy of the computer system is at least 99%. In some embodiments, the diagnostic accuracy of the computer system is at least 98%. In some embodiments, the diagnostic accuracy of the computer system is at least 95%. In some embodiments, the diagnostic accuracy of the computer system is at least 90%. In some embodiments, the diagnostic accuracy of the computer system is 85%. In some embodiments, the diagnostic accuracy of the computer system is at least 80%.
- the present invention utilizes metabolites comprising carbohydrates, amino acids, fatty acids and/or nucleotides and their derivatives.
- the present invention is for a patient who is asymptomatic or symptomatic for pulmonary hypertension, diabetes mellitus, heart disease, lung diseases, chronic liver, kidney diseases, cancers and other chronic or acute conditions characterized with metabolic changes in the mitochondria, alterations in glycolytic pathways, protein biosynthesis/oxidation, fatty acids biosynthesis/oxidations, etc.
- the biological sample is easily obtained from the patient and can comprise plasma, serum, urine, lung fluids, lavage, etc.
- the metabolites are measured throughout time in biological samples obtained from subjects longitudinally throughout time.
- longitudinal timing points comprise 1) an initial time comprising at time of no symptoms, at time of diagnosis, or at initial presentation of symptoms; 2) about weekly intervals post initial time; 3) about monthly intervals post initial time; and/or 4) about yearly intervals.
- the disease comprises pulmonary arterial hypertension (PAH), Diabetes Mellitus (DM), left heart disease, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), head and neck cancer, thyroid cancer or colon cancer.
- PAH pulmonary arterial hypertension
- DM Diabetes Mellitus
- COPD chronic obstructive pulmonary disease
- ILD interstitial lung disease
- the method is able to differentiate between PAH, DM, and left heart disease.
- the metabolic biomarker panel is distinctly different in subjects with pulmonary arterial hypertension (PAH) compared to subjects with Diabetes Mellitus (DM) or left heart disease.
- the method may be used for pre-screening the subject either to identify pulmonary arterial hypertension (PAH) at the asymptomatic stage or to minimize the time for PAH diagnosis after the initial symptom onset.
- the method is used for determining the severity of PAH in the patient.
- the method discriminates between pulmonary arterial hypertension (PAH) and classical metabolic disorders, including diabetes mellitus (DM), or left heart diseases.
- the method is used in subjects with other diseases comprising cancer, lung diseases, and systemic hypertension.
- the method is used to guide treatment and/or care management of the subject diagnosed with pulmonary arterial hypertension (PAH).
- the subject does not display clinical symptoms (i.e., asymptomatic) or does display clinical symptoms (i.e., symptomatic) for pulmonary arterial hypertension (PAH), DM, left heart diseases, lung diseases, kidney and liver disease, cancers or other acute and chronic conditions characterized with metabolic changes, wherein symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- PAH pulmonary arterial hypertension
- DM left heart diseases
- lung diseases left heart diseases
- kidney and liver disease cancers or other acute and chronic conditions characterized with metabolic changes
- symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- a biological sample may comprise plasma, serum, or urine, obtained from the subject.
- the present invention may further feature a method of treating a subject with pulmonary arterial hypertension (PAH).
- PAH pulmonary arterial hypertension
- the method comprises determining the expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject.
- the method comprises treating PAH in a subject identified as having differing levels of the panel of metabolic biomarkers when compared to the levels of said metabolic biomarkers in a normal subject.
- the panel of metabolic biomarkers comprises oxalic acid, aminomalonate, pseudouridine, gluconic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid, glutamic acid, phosphate, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- the subject with PAH has a higher level of oxalic acid, aminomalonate, pseudouridine, gluconic acid, uric acid, UDP-glucuronic acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid, glutamic acid, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, oxoproline than the normal subject.
- the subject with PAH has a lower level of erythritol, fumaric acid, and phosphate than the normal subject.
- the expression data of the panel of metabolic biomarkers is determined using standard clinical chemistry techniques, protein analytic techniques, nucleic acid techniques, and/or analytical techniques suitable for metabolite analysis (e.g., Gas chromatography—time of flight mass spectrometry (GC-TOF) mass spectrometry, liquid chromatography mass spectrometry (LCMS), Nuclear magnetic resonance (NMR)).
- GC-TOF Gas chromatography—time of flight mass spectrometry
- LCMS liquid chromatography mass spectrometry
- NMR Nuclear magnetic resonance
- the method is used for determining the severity of PAH in the subject.
- the subject does not display clinical symptoms (i.e., asymptomatic) or does display clinical symptoms (i.e., symptomatic) for pulmonary arterial hypertension (PAH), DM, left heart diseases, lung diseases, kidney and liver disease, cancers or other acute and chronic conditions characterized with metabolic changes, wherein symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- the method is used to guide treatment and/or care management of the subject diagnosed with pulmonary arterial hypertension (PAH).
- the biological sample comprises plasma, serum, urine, obtained from the subject.
- the treatment of pulmonary hypertension comprises administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and/or balloon angioplasty.
- the present invention may feature a non-transitory, computer-readable medium having computer executable instructions for causing a processor to execute a method for diagnosing a subject with a disease.
- the method comprises determining whether expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is indicative of the disease using a trained machine learning classifier for distinguishing subjects with different diseases and without disease.
- the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having the disease and from control subjects that do not have disease.
- the method comprises diagnosing the subject if the expression data is correlated to be indicative of the disease. In some embodiments, the diagnostic accuracy is at least 90%.
- the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- oxalic acid
- the present invention may also feature a kit for diagnosing a subject with a disease.
- the kit comprises one or more reference metabolic biomarker panels (see Table 1, 2, 3).
- the kit comprises a non-transitory, computer-readable medium described herein.
- expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is inputted into a computer that executes the computer executable instructions of the non-transitory, computer-readable medium.
- a subject is diagnosed with disease when the expression data of the panel of metabolic biomarkers in the biological subject is correlated with the one or more reference metabolic biomarker panels by the computer to be indicative of disease and where the diagnostic accuracy is at least 90%.
- the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- oxalic acid
- the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- the expression data of the panel of metabolic biomarkers is determined using standard clinical chemistry techniques, protein analytic techniques, nucleic acid techniques, and/or analytical techniques suitable for metabolite analysis (e.g., Gas chromatography—time of flight mass spectrometry (GC-TOF) mass spectrometry, liquid chromatography mass spectrometry (LCMS), Nuclear magnetic resonance (NMR)).
- GC-TOF Gas chromatography—time of flight mass spectrometry
- LCMS liquid chromatography mass spectrometry
- NMR Nuclear magnetic resonance
- the metabolites are measured throughout time in biological samples obtained from subjects longitudinally throughout time.
- longitudinal timing points comprise 1) an initial time comprising at time of no symptoms, at time of diagnosis, or at initial presentation of symptoms; 2) about weekly intervals post initial time; 3) about monthly intervals post initial time; and/or 4) about yearly intervals.
- the disease comprises pulmonary arterial hypertension (PAH), Diabetes Mellitus (DM), left heart disease, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), head and neck cancer, thyroid cancer or colon cancer.
- PAH pulmonary arterial hypertension
- DM Diabetes Mellitus
- COPD chronic obstructive pulmonary disease
- ILD interstitial lung disease
- the method is able to differentiate between PAH, DM, and left heart disease.
- the metabolic biomarker panel is distinctly different in subjects with pulmonary arterial hypertension (PAH) compared to subjects with Diabetes Mellitus (DM) or left heart disease.
- the kit may be used for pre-screening the subject either to identify pulmonary arterial hypertension (PAH) at the asymptomatic stage or to minimize the time for PAH diagnosis after the initial symptom onset.
- the kit is used for determining the severity of PAH in the patient.
- the kit discriminates between pulmonary arterial hypertension (PAH) and classical metabolic disorders, including diabetes mellitus (DM), or left heart diseases.
- the kit is used in subjects with other diseases comprising cancer, lung diseases, and systemic hypertension.
- the method is used to guide treatment and/or care management of the subject diagnosed with pulmonary arterial hypertension (PAH).
- the subject does not display clinical symptoms (i.e., asymptomatic) or does display clinical symptoms (i.e., symptomatic) for pulmonary arterial hypertension (PAH), DM, left heart diseases, lung diseases, kidney and liver disease, cancers or other acute and chronic conditions characterized with metabolic changes, wherein symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- PAH pulmonary arterial hypertension
- DM left heart diseases
- lung diseases left heart diseases
- kidney and liver disease cancers or other acute and chronic conditions characterized with metabolic changes
- symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- the subject is asymptomatic or symptomatic for PAH, DM, left heart disease, wherein an asymptomatic patient does not display clinical symptoms of PAH, DM, left heart disease and asymptomatic patient displays clinical symptoms of PAH, DM, left heart disease comprising shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- the 36 metabolites (Table 1) comprise mitochondrial-derived metabolites, carbohydrates, metabolites of myo-inositol and its derivatives, and/or metabolites that are indicative of damage known to be directly associated with PAH or an altered gut microbiome, and/or metabolites associated with PAH pathogenesis.
- mitochondrial-derived metabolites comprise tricarboxylic acid (TCA) metabolites and their derivatives, including oxalic acid.
- the metabolomic biomarker panel is distinctly different in patients with PAH compared to diabetic patients or patients with left heart diseases.
- the tools, methods, and kits described herein using the metabolomic profile or fingerprint is used for 1) pre-screening of patients either to identify PAH at the asymptomatic stage or to minimize the time for PAH diagnosis after the initial symptom onset; 2) determining the severity of PAH in a patient; 3) discriminating between PAH and classical metabolic disorders (e.g., DM) or left heart diseases that often mimic the symptoms of right heart disease; 4) patient cohorts with other diseases comprising cancer, lung diseases, and systemic hypertension; and 5) treatment and/or care management of a patient suspected of having or has PAH.
- classical metabolic disorders e.g., DM
- 36 unique plasma metabolites or markers differentiate patients with PAH, DM, and left heart diseases. Of the 36 metabolites that are significantly altered in PAH as compared to diabetes mellitus and left heart diseases.
- symptomatic patients comprise patients with clinical symptoms of pulmonary stress, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- asymptomatic patients do not overtly display the aforementioned clinical symptoms.
- the present invention also features an in vitro method for diagnosing, monitoring, or treating a patient suffering pulmonary arterial hypertension (PAH) in a patient.
- the method comprises first obtaining a biological sample from the patient.
- a biological sample comprise an easily obtained sample from a patient, e.g., plasma, serum, blood, and/or urine.
- Targeted metabolomics is then performed to determine levels of metabolites, which are measured in the biological sample using standard analytical techniques including GC-TOF mass spectrometry.
- the metabolites comprise oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, uridine diphosphate (UDP)-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- UDP uridine diphosphate
- the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- a metabolic profile is then determined based on the measured level of at least five metabolites.
- the profile is a metabolic fingerprint that distinguishes patients with PAH as compared to those with Diabetes Mellitus (DM) and/or left heart disease.
- the patient is then diagnosed for PAH based on the metabolic profiled fingerprint that distinguishes patients with PAH as compared to those with Diabetes Mellitus (DM) and/or left heart disease.
- the patient is then monitored throughout time for reduction, progression, or stable disease of PAH based on the metabolic profiled fingerprint that distinguishes patients with PAH as compared to those with DM and/or left heart disease.
- longitudinal timepoints to measure the metabolites comprise at initial assessment for PAH, presentation of initial symptoms of PAH or diagnosis PAH, and then weekly, monthly, and/or yearly timepoints.
- pulmonary hypertension/PAH may be selected from the group consisting of the administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and balloon angioplasty.
- the present invention includes a computer system that can execute the methods for diagnosing a disease as described herein.
- the invention employs a computer device or computer-implemented method having one or more processors and at least one memory, the at least one memory storing non-transitory computer-readable instructions for execution by the one or more processors to cause the one or more processors to execute instructions (or stored data) in one or more modules.
- the instructions may be stored in a non-transitory computer-readable medium or computer-usable medium.
- a computer system can include a desktop computer, a laptop computer, a tablet, or the like and can include digital electronic circuitry, firmware, hardware, memory, a computer storage medium, a computer program, a processor (including a programmed processor), or the like.
- the computing system may include a desktop computer with a screen and a tower.
- processor encompasses all kinds of apparatus, devices, and machines for processing data, including by way of example a programmable microprocessor, a computer, a system on a chip, or multiple ones, or combinations, of the foregoing.
- the apparatus can include special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application-specific integrated circuit).
- the apparatus also can include, in addition to hardware, code that creates an execution environment for the computer program in question, e.g., code that constitutes processor firmware, a protocol stack, a database management system, an operating system, a cross-platform runtime environment, a virtual machine, or a combination of one or more of them.
- the apparatus and execution environment can realize various different computing model infrastructures, such as web services, distributed computing and grid computing infrastructures.
- the processor may include one or more processors of any type, such as central processing units (CPUs), graphics processing units (GPUs), special-purpose signal or image processors, field-programmable gate arrays (FPGAs), tensor processing units (TPUs), and so forth.
- CPUs central processing units
- GPUs graphics processing units
- FPGAs field-programmable gate arrays
- TPUs tensor processing units
- a computer program (also known as a program, software, software application, script, or code) can be written in any form of programming language, including compiled or interpreted languages, declarative or procedural languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, object, or other unit suitable for use in a computing environment.
- a computer program may, but need not, correspond to a file in a file system.
- a program can be stored in a portion of a file that holds other programs or data (e.g., one or more scripts stored in a markup language document), in a single file dedicated to the program in question, or in multiple coordinated files (e.g., files that store one or more modules, subprograms, or portions of code).
- a computer program can be deployed to be executed on one computer or on multiple computers that are located at one site or distributed across multiple sites and interconnected by a communication network.
- Embodiments of the subject matter and the operations described herein can be implemented in digital electronic circuitry, or in computer software, firmware, or hardware, including the structures disclosed in this specification and their structural equivalents, or in combinations of one or more of them.
- Embodiments described in this specification can be implemented as one or more computer programs, i.e., one or more modules of computer program instructions, encoded on computer storage medium for execution by, or to control the operation of, data processing apparatus. Any of the modules described herein may include logic that is executed by the processor(s).
- Logic refers to any information having the form of instruction signals and/or data that may be applied to affect the operation of a processor.
- Software is an example of logic.
- Logic may be formed from signals stored on a computer-readable medium such as memory that, in an exemplary embodiment, may be a random access memory (RAM), read-only memories (ROM), erasable/electrically erasable programmable read-only memories (EPROMS/EEPROMS), flash memories, etc.
- Logic may also comprise digital and/or analog hardware circuits, for example, hardware circuits comprising logical AND, OR, XOR, NAND, NOR, and other logical operations.
- Logic may be formed from combinations of software and hardware. On a network, logic may be programmed on a server, or a complex of servers. A particular logic unit is not limited to a single logical location on the network. Moreover, the modules need not be executed in any specific order. Each module may call another module when needed to be executed.
- a computer storage medium can be, or can be included in, a computer-readable storage device, a computer-readable storage substrate, a random or serial access memory array or device, or a combination of one or more of them.
- a computer storage medium is not a propagated signal, a computer storage medium can be a source or destination of computer program instructions encoded in an artificially generated propagated signal.
- the computer storage medium can also be, or can be included in, one or more separate physical components or media (e.g., multiple CDs, disks, or other storage devices).
- the operations described in this specification can be implemented as operations performed by a data processing apparatus on data stored on one or more computer-readable storage devices or received from other sources.
- Program code embodied on a computer readable medium may be transmitted using any appropriate medium, including but not limited to wireless, wireline, optical fiber cable, R.F, etc., or any suitable combination of the foregoing.
- Computer program code for carrying out operations for aspects of the present disclosure may be written in any combination of one or more programming languages, including an object oriented programming language such as Java, Smalitalk, C++ or the like and conventional procedural programming languages, such as the “C” programming language or similar programming languages.
- the program code may execute entirely on the user's computer, partly on the user's computer, as a stand-alone software package, partly on the user's computer and partly on a remote computer or entirely on the remote computer or server.
- the remote computer may be connected to the user's computer through any type of network, including a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider).
- LAN local area network
- WAN wide area network
- Internet Service Provider an Internet Service Provider
- the processes and logic flows described in this specification can be performed by one or more programmable processors executing one or more computer programs to perform actions by operating on input data and generating output.
- the processes and logic flows can also be performed by, and apparatus can also be implemented as, special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application-specific integrated circuit).
- processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processors of any kind of digital computer.
- a processor will receive instructions and data from a read-only memory or a random access memory or both.
- the essential elements of a computer are a processor for performing actions in accordance with instructions and one or more memory devices for storing instructions and data.
- a computer will also include, or be operatively coupled to receive data from or transfer data to, or both, one or more mass storage devices for storing data, e.g., magnetic, magneto-optical disks, or optical disks.
- a computer need not have such devices.
- a computer can be embedded in another device, e.g., a mobile telephone, a personal digital assistant (PDA), a mobile audio or video player, a game console, a Global Positioning System (GPS) receiver, or a portable storage device (e.g., a universal serial bus (USB) flash drive), to name just a few.
- Devices suitable for storing computer program instructions and data include all forms of non-volatile memory, media and memory devices, including by way of example semiconductor memory devices, e.g., EPROM, EEPROM, and flash memory devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks.
- the processor and the memory can be supplemented by, or incorporated in, special purpose logic circuitry.
- One or more computing devices such as desktop computers, laptop computers, tablets, smartphones, servers, application-specific computing devices, or any other type(s) of electronic device(s) may be capable of performing the techniques and operations described herein.
- the system may be implemented as a single device.
- the system may be implemented as a combination of two or more devices together.
- the system may include one or more server computers and a one or more client computers communicatively coupled to each other via one or more local-area networks and/or wide-area networks such as the Internet.
- Computers typically include known components, such as a processor, an operating system, system memory, memory storage devices, input-output controllers, input-output devices, and display devices. It will also be understood by those of ordinary skill in the relevant art that there are many possible configurations and components of a computer and may also include cache memory, a data backup unit, and many other devices.
- a display device e.g., an LCD (liquid crystal display). LED (light emitting diode) display, or OLED (organic light emitting diode) display, for displaying information to the user.
- LED light emitting diode
- OLED organic light emitting diode
- Examples of input devices include a keyboard, cursor control devices (e.g., a mouse or a trackball), a microphone, a scanner, and so forth, wherein the user can provide input to the computer.
- Other kinds of devices can be used to provide for interaction with a user as well; for example, feedback provided to the user can be in any form of sensory feedback, e.g., visual feedback, auditory feedback, or tactile feedback; and input from the user can be received in any form, including acoustic, speech, or tactile input.
- Examples of output devices include a display device (e.g., a monitor or projector), speakers, a printer, a network card, and so forth.
- Display devices may include display devices that provide visual information, this information typically may be logically and/or physically organized as an array of pixels.
- a computer can interact with a user by sending documents to and receiving documents from a device that is used by the user; for example, by sending web pages to a web browser on a user's client device in response to requests received from the web browser.
- An interface controller may also be included that may comprise any of a variety of known or future software programs for providing input and output interfaces.
- interfaces may include what are generally referred to as “Graphical User Interfaces” (often referred to as GUI's) that provide one or more graphical representations to a user. Interfaces are typically enabled to accept user inputs using means of selection or input known to those of ordinary skill in the related art.
- GUI's Graphic User Interfaces
- the interface may be a touch screen that can be used to display information and receive input from a user.
- applications on a computer may employ an interface that includes what are referred to as “command line interfaces” (often referred to as CLI's).
- CLI's typically provide a text based interaction between an application and a user.
- command line interfaces present output and receive input as lines of text through display devices.
- some implementations may include what are referred to as a “shell” such as Unix Shells known to those of ordinary skill in the related art, or Microsoft Windows Powershell that employs object-oriented type programming architectures such as the Microsoft .NET framework.
- interfaces may include one or more GUI's, CLI's or a combination thereof.
- a processor may include a commercially available processor such as a Celeron, Core, or Pentium processor made by Intel Corporation, a SPARC processor made by Sun Microsystems, an Athlon, Sempron, Phenom, Ryzen or Opteron processor made by AMD Corporation, or it may be one of other processors that are or will become available.
- Some embodiments of a processor may include a multi-core processor and/or be enabled to employ parallel processing technology in a single or multi-core configuration.
- a multi-core architecture typically comprises two or more processor “execution cores”.
- Each execution core may perform as an independent processor that enables parallel execution of multiple threads.
- a processor may be configured in what is generally referred to as 32 or 64 bit architectures, or other architectural configurations now known or that may be developed in the future.
- a processor typically executes an operating system, which may be, for example, a Windows type operating system from the Microsoft Corporation; the Mac OS X op-crating system from Apple Computer Corp.; a Unix or Linux-type operating system available from many vendors or what is referred to as an open source; another or a future operating system; or some combination thereof.
- An operating system interfaces with firmware and hardware in a well-known manner, and facilitates the processor in coordinating and executing the functions of various computer programs that may be written in a variety of programming languages.
- An operating system typically in cooperation with a processor, coordinates and executes functions of the other components of a computer.
- An operating system also provides scheduling, input-output control, file and data management, memory management, and communication control and related services, all in accordance with known techniques.
- Embodiments of the subject matter described in this specification can be implemented in a computing system that includes a back-end component, e.g., as a data server, or that includes a middleware component, e.g., an application server, or that includes a front-end component, e.g., a client computer having a graphical user interface or a Web browser through which a user can interact with an implementation of the subject matter described in this specification, or any combination of one or more such back-end, middleware, or front-end components.
- the components of the system can be interconnected by any form or medium of digital data communication, e.g., a communication network.
- Examples of communication networks include a local area network (“LAN”) and a wide area network (“WAN”), an inter-network (e.g., the Internet), and peer-to-peer networks (e.g., ad hoc peer-to-peer networks).
- the network can include one or more local area networks.
- the computing system can include any number of clients and servers. A client and server are generally remote from each other and typically interact through a communication network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.
- a server transmits data (e.g., an HTML page) to a client device (e.g., for purposes of displaying data to and receiving user input from a user interacting with the client device).
- data generated at the client device e.g., a result of the user interaction
- a computer may include one or more library files, experiment data files, and an internet client stored in system memory.
- experiment data could include data related to one or more experiments or assays, such as detected signal values, or other values associated with the biomarker expression data.
- an internet client may include an application enabled to access a remote service on another computer using a network and may for instance comprise what are generally referred to as “Web Browsers”, In the present example, some commonly employed web browsers include Microsoft Internet Explorer available from Microsoft Corporation, Nilozilla Firefox from the Mozlla Corporation, Safari from Apple Computer Corp., Google Chrome from the Google Corporation, or other type of web browser currently known in the art or to be developed in the future.
- an Internet client may include, or could be an element of, specialized software applications enabled to access remote information via a network such as a data processing application for biological applications.
- a network may include one or more of the various types of networks known to those of ordinary skill in the art.
- a network may include a local or wide area network that may employ what is commonly referred to as a TCP/IP protocol suite to communicate.
- a network may include a network comprising a worldwide system of interconnected computer networks that is commonly referred to as the internet, or could also include various intranet architectures.
- Firewalls also sometimes referred to as Packet Filters, or Border Protection De-vices
- firewalls may comprise hardware or software elements or some combination thereof and are typically designed to enforce security policies put in place by users, such as for instance network administrators, etc.
- instructions cause at least one of the processors of the computer system to receive an input, which is expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject i.
- a module is then executed to derive object features and context features and to calculate object feature metrics and context feature metrics.
- the object feature metrics and context feature metrics are provided to a trained end classifier, which classifies the object and provides an output to the user.
- the output may be to a display, a memory, or any other means suitable in the art.
- Example 1 Metabolic Profile of Patients with PAH as Compared to Those with Diabetes Mellitus and Left Heart Disease
- the plasma metabolic profiles were examined in patients with idiopathic PAH, patients with type 2 diabetes mellitus (DM) (University of Arizona (UA) Center for Disparities in Diabetes, Obesity, and Metabolism) and patients with left heart diseases (Heart) (UA biobank). Groups were matched for age (mean ⁇ STD): 41.1 ⁇ 15.7; 41.8 ⁇ 13.7; 50.2 ⁇ 10.9; and sex female/male (%): 81.8/18.1; 83.3/16.7; 72.7/27.3; for PAH, DM and Heart, respectively.
- Targeted metabolomic analysis was used to quantify primary plasma metabolites, including carbohydrates, amino acids, and nucleotides by GC-TOF mass spectrometry. Two runs of profiling were acquired separately, PAH versus DM and PAH versus Heart. In the DM/PAH run, from the 172 metabolites detected, 84 metabolites were significantly altered (p ⁇ 0.05). A comparison of PAH and Heart groups showed 76 significantly changed metabolites among 158 that were identified. Heat maps in FIG. 1 A show characteristic clustering of PAH group, distinguishing them from DM and Heart patients. Principal component analysis (PCA) of significantly changed metabolites showed clear separation of PAH sub-population from DM and Heart patients ( FIG. 1 B ). The results of this analysis indicate that the plasma metabolomics profile is distinctly different in patients with PAH compared to diabetic patients or patients with left heart diseases. Therefore, the plasma metabolome has a strong potential to serve as a diagnostic tool.
- PCA Principal component analysis
- the primary group of metabolites consists of mitochondrial-derived metabolites, including tricarboxylic acid (TCA) metabolites and their derivatives.
- TCA tricarboxylic acid
- Oxalic acid the product of oxaloacetate decomposition, was increased over 20-fold in PAH. These changes may indicate undergoing anaplerotic reactions resulting in an accumulation of oxaloacetate, as well as other TCA metabolites.
- the next largest group of metabolites consists of carbohydrates. This could be an indication of altered glycolysis due to the metabolic shift associated with PAH pathogenesis. Vascular remodeling in PAH could be the main reason for a decreased level of circulating amino acids, the primary building blocks of proteins that are highly consumed by proliferating cells.
- the last two groups of metabolites contain metabolites that are indicative of damage known to be directly associated with PAH, or an altered gut microbiome, which has also been implemented/implicated in PAH pathogenesis.
- a metabolite optimization approach and regression analysis identified the minimal number of metabolites sufficient for a significant separation of PAH group from DM and Heart.
- eleven metabolites were used to distinguish PAH samples from other patients.
- Ellipses showed the area of 0.95 probability that patients from the specific group will fall inside the ellipse area. This analysis indicates that although there is some small intersection between DM and Heart groups, PAH patients were well resolved from both diseases.
- the panel of eleven metabolites comprises oxalic acid, pseudouridine, gluconic acid, fumaric acid, UDP-glucuronic acid, aconitic acid, erythritol, 2-deoxytetronic acid, glutamic acid, inorganic phosphate, and 2-hydroxyglutaric acid and can be used for the pre-screening of patients either to identify PAH at the asymptomatic stage or help to minimize the time for PAH diagnosis after the initial symptom onset reported to be currently 47.1 ⁇ 34.2 months.
- the present invention features application or use of metabolic profiling as a new diagnostic method and provides subsequent research with a specific set of preselected metabolites that could serve as a fingerprint of PAH and/or discerning the pathogenesis of PAH.
- the term “about” refers to plus or minus 10% of the referenced number.
- descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting essentially of” or “consisting of”, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting essentially of” or “consisting of” is met.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Primary Health Care (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Databases & Information Systems (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Artificial Intelligence (AREA)
- Genetics & Genomics (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Pharmacology & Pharmacy (AREA)
Abstract
Description
- This application claims benefit of U.S. Provisional Application No. 62/960,951 filed Jan. 14, 2020, the specification(s) of which is/are incorporated herein in their entirety by reference.
- This invention was made with government support under Grant Nos. R01 HL132918 and R01 HL133085 awarded by National Institutes of Health. The government has certain rights in the invention.
- Pulmonary arterial hypertension (PAH), a condition in which elevated pressure is found in the pulmonary artery, is an incurable, progressive disorder, and early diagnosis and treatment of PAH are associated with increased survival. However, due to the asymptomatic nature of PAH development as well as PAH's symptomatic similarity to hypertension from metabolic disorders (e.g.,
type 2 Diabetes Mellitus, DM) or left heart disease, there are severe delays in PAH diagnosis. In most cases, therapy starts only at an advanced stage of the disease and if it is not successfully treated, it can lead to right ventricular hypertrophy and right-sided heart failure. As such, there is a critical need to improve diagnostic approaches for diagnosis of PAH in its early stages and differentiation of similar pathologies. - The present invention relates to diagnosing and monitoring PAH in a patient. The present invention features an in vitro diagnostic (IVD) tool comprising a metabolomic biomarker panel representing a profile or fingerprint and methods of using the profile or fingerprint for diagnosing and monitoring PAH; the profile comprises a unique panel of 36 biomarkers (e.g., a fingerprint) that can be detected in easily obtained specimens from a patient, for example, plasma, serum and/or urine. Without wishing to limit the present invention to any particular theory or mechanism, it is believed that metabolic reprogramming occurs early in the development of the disease and foreshadows pathophysiological changes. The present invention assesses a profile of circulating metabolites that uniquely allows the identification of patients with PAH at an early stage of disease, before the condition has progressed sufficiently to produce clinical symptoms. The profile or fingerprint distinguishes PAH from hypertension due to
type 2 Diabetes Mellitus (DM) and left heart disease. The present invention features a set of metabolites for early diagnosis of PAH comprising—oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, uridine diphosphate (UDP)-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline The present invention can be used for pre-screening of patients either to identify PAH at the asymptomatic stage or help to minimize the time for PAH diagnosis after the initial symptom onset. - Pulmonary arterial hypertension (PAH) induces a distinct signature of circulating metabolites. Several previous reports were focused on the metabolic profiling of plasma and lung samples from pre-clinical models and patients. However, these prior comparisons were derived from healthy controls as described herein. It is more important to identify the markers that distinct PAH from other pathologies, which may show alterations of similar metabolites described herein. Metabolic reprogramming and a significant component of cardiac changes in PAH could mask PAH among more abundant conditions, such as metabolic disorders or left heart diseases. The present invention differentiates the plasma metabolic profiles of patients with idiopathic PAH, patients with
type 2 diabetes mellitus (DM) and patients with left heart diseases (Heart). - Patients with idiopathic pulmonary arterial hypertension (IPAH) are particularly likely to be diagnosed at a late stage of the disease because the symptoms are nonspecific; diagnosis requires complex or invasive tests. This has increased the need for better diagnostic tools.
- To date, there are no inexpensive, non-invasive specific screening tools. An increase in pulmonary artery pressure can be estimated by transthoracic echocardiography. It is currently used for screening, but in patients with PH, it often over- or under-estimates pulmonary arterial pressure and cardiac output. Nevertheless, echocardiography is a generally preferred non-invasive imaging modality for PH screening. Right heart catheterization is a standard diagnostic method for diagnosis but is not suitable for screening because it is invasive. Early recognition of the disease is a high priority and additional diagnostic and non-invasive screening tools need to be developed.
- Biomarkers specifically indicating disease, disease stage, and treatment response to a particular treatment are ideal tools for optimization of pulmonary hypertension management. In addition, monitoring of pulmonary hypertension via biomarkers is important to better determine the urgency of lung transplantation in patients with diseases that are difficult to treat.
- The present invention uses targeted metabolomics to quantify primary plasma metabolites or biomarkers, including carbohydrates, amino acids, and nucleotides for example by GC-TOF mass spectrometry. The present invention shows that the plasma metabolomics profile is distinctly different in patients with PAH compared to diabetic patients or patients with left heart diseases. Therefore, the unique plasma metabolome described herein has a strong potential to serve as a diagnostic tool.
- The present invention shows that 36 unique metabolites are significantly altered in PAH patients compared to either diabetics or left heart patients or healthy people (Table 1) and could be used as a fingerprint for PAH. These unique metabolites can be classified into a few major groups comprising mitochondrial-derived metabolites, carbohydrates, myo-inositol and its derivatives, and metabolites that are indicative of damage known to be directly associated with PAH or an altered gut microbiome. Of these 36 metabolites, a minimum of 5 metabolites are critical for diagnosis of PAH and to differentiate PAH from DM or left heart disease.
-
TABLE 1 Metabolites that are significantly different in PAH cohort vs. heart or DM cohorts (a minimum of five (5) metabolites critical for the diagnosis for PAH and to differentiate PAH from DM or left heart disease). A fold change less than 1.0 in the healthy control indicates that the metabolite is decreased in PAH compared to the compared cohort. A fold change greater than 1.0 in the healthy control indicates that the metabolite is increased in PAH compared to the compared cohort. Fold Fold Fold Metabolites Heart p-value DM p-value Healthy p-value oxalic acid 45.23 4.35 × 10−5 82.10 2.24 × 10−8 156.36 1.69 × 10−8 aminomalonate 3.00 6.52 × 10−5 2.75 6.12 × 10−3 6.60 2.66 × 10−8 pseudouridine 2.62 2.31 × 10−4 3.07 8.86 × 10−5 2.44 3.04 × 10−3 gluconic acid 2.35 6.25 × 10−8 1.55 1.33 × 10−2 2.52 1.11 × 10−2 isothreonic acid 2.05 1.31 × 10−5 2.09 9.85 × 10−4 4-hydroxyphenylacetic acid 2.02 1.57 × 10−2 2.24 2.77 × 10−3 erythritol 2.01 3.16 × 10−3 2.83 1.56 × 10−3 0.10 7.27 × 10−2 uric acid 1.99 2.28 × 10−3 1.79 4.85 × 10−2 4.12 7.98 × 10−7 UDP-glucuronic acid 1.98 4.45 × 10−3 4.49 2.77 × 10−4 4.49 3.08 × 10−1 fumaric acid 1.95 3.81 × 10−5 1.37 1.16 × 10−2 0.77 4.94 × 10−5 focuse 1.86 1.68 × 10−3 1.68 3.40 × 10−3 aconitic acid 1.86 5.21 × 10−5 3.14 1.68 × 10−9 4.64 3.57 × 10−1 2-deoxytetronic acid 1.78 1.36 × 10−2 2.17 7.04 × 10−5 2.53 3.86 × 10−1 pantothenic acid 1.75 7.33 × 10−3 1.69 8.60 × 10−4 indole-3-acetate 1.59 9.92 × 10−3 2.06 1.16 × 10−3 myo-inositol 1.50 2.52 × 10−2 1.65 2.32 × 10−2 2.33 9.44 × 10−3 2-hydroxyvaleric acid 1.48 3.27 × 10−2 2.12 5.16 × 10−3 citric acid 1.48 2.97 × 10−2 2.01 1.81 × 10−4 1.96 1.34 × 10−5 ribonic acid 1.48 6.03 × 10−4 2.61 5.75 × 10−4 glycine 1.44 5.18 × 10−2 1.41 4.17 × 10−2 glutamic acid 1.40 4.91 × 10−2 0.68 3.59 × 10−2 1.74 4.02 × 10−2 creatinine 1.38 1.55 × 10−2 1.58 8.82 × 10−4 glucuronic acid 1.37 8.21 × 10−4 2.66 1.77 × 10−4 phosphate 1.28 4.56 × 10−2 4.54 2.09 × 10−11 0.23 1.27 × 10−17 indole-3-lactate 1.26 3.59 × 10−2 1.85 4.37 × 10−6 urea 1.21 2.91 × 10−2 1.47 2.49 × 10−2 2-hydroxyglutaric acid 0.78 2.88 × 10−2 1.55 2.80 × 10−4 tryptophan 0.76 4.66 × 10−3 0.51 7.55 × 10−8 tyrosine 0.74 7.99 × 10−3 0.67 3.43 × 10−5 glutamine 0.73 4.99 × 10−3 0.71 2.97 × 10−2 lysine 0.72 4.38 × 10−4 0.56 2.20 × 10−6 histidine 0.51 1.34 × 10−5 0.45 8.65 × 10−7 N-acetylornithine 7.56 4.14 × 10−6 2-hydroxybutanoic acid 5.26 3.89 × 10−5 alpha-ketoglutarate 3.19 8.73 × 10−5 oxoproline 1.74 3.31 × 10−7 - The present invention shows the value of metabolic profiling as a new diagnostic tool and provides subsequent research with a specific set of preselected metabolites that could serve as a fingerprint of PAH. The present invention also highlights the potential value of the particular metabolites in dissecting the pathogenesis of PAH.
- It is an objective of the present invention to provide diagnostic and monitoring and treatment methods for PAH that allow for early diagnosis of PAH and distinction from DM and/or left heart disease, as specified in the independent claims. Embodiments of the invention are given in the dependent claims. Embodiments of the present invention can be freely combined with each other if they are not mutually exclusive.
- One of the unique and inventive technical features of the present invention is using a profile or panel (fingerprint) of 5 out of 36 metabolites for early diagnosis of PAH. Without wishing to limit the invention to any theory or mechanism, it is believed that the technical feature of the present invention advantageously provides for differentiating PAH from DM and/or left heart disease. None of the presently known prior references or work has the unique inventive technical feature of the present invention.
- Furthermore, the prior references teach away from the present invention. For example, metabolites described herein are also present and/or altered in similar PH pathologies from metabolic disorders (e.g., DM; left heart disease) and it would be counterintuitive or not obvious that these select metabolites can differentiate PAH from DM and/or left heart disease.
- Furthermore, the inventive technical feature of the present invention contributed to a surprising result. For example, the inventors of the present invention surprisingly found that the determination of the level of five or more of the aforementioned 36 metabolites of a patient-derived biological sample enables diagnosis of PAH and differentiation from DM and left heart disease even though these metabolites are also altered in DM and left heart disease.
- The present invention features a computer-implemented method for diagnosing a subject with a disease. In some embodiments, the method comprises inputting expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject. In other embodiments, the method comprises determining whether expression of the metabolic biomarkers in the biological sample obtained from the subject is indicative of a disease using a computer system programmed with a trained machine learning classifier for distinguishing subjects with different diseases and without disease. In some embodiments, the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having disease and from control subjects that do not have disease. In some embodiments, the method comprises diagnosing the subject. In some embodiments, the expression data of the panel of metabolic biomarkers in the biological sample obtained from the subject is correlated by the computer system to be indicative of disease; and where the diagnostic accuracy is at least 90%. In other embodiments, the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, oxoproline. In further embodiments, the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid
- The present invention may further feature a method of treating a subject with pulmonary arterial hypertension (PAH). In some embodiments, the method comprises determining the expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject. In some embodiments, the method comprises treating PAH in a subject identified as having differing levels of the panel of metabolic biomarkers when compared to the levels of said metabolic biomarkers in a normal subject. In other embodiments, the panel of metabolic biomarkers comprises oxalic acid, aminomalonate, pseudouridine, gluconic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid, glutamic acid, phosphate, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline. In further embodiments, the subject with PAH has a higher level of oxalic acid, aminomalonate, pseudouridine, gluconic acid, uric acid, UDP-glucuronic acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid. glutamic acid. N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, oxoproline than the normal subject. In other embodiments, the subject with PAH has a lower level of erythritol, fumaric acid, and phosphate than the normal subject.
- The present invention may feature a non-transitory, computer-readable medium having computer executable instructions for causing a processor to execute a method for diagnosing a subject with a disease. In some embodiments, the method comprises determining whether expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is indicative of the disease using a trained machine learning classifier for distinguishing subjects with different diseases and without disease. In some embodiments, the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having the disease and from control subjects that do not have disease. In some embodiments, the method comprises diagnosing the subject if the expression data is correlated to be indicative of the disease. In some embodiments, the diagnostic accuracy is at least 90%. In other embodiments, the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- The present invention may also feature a kit for diagnosing a subject with a disease. In some embodiments, the kit comprises one or more reference metabolic biomarker panels (see Table 1, 2, 3). In other embodiments, the kit comprises a non-transitory, computer-readable medium described herein. In some embodiments, expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is inputted into a computer that executes the computer executable instructions of the non-transitory, computer-readable medium. In other embodiments, a subject is diagnosed with disease when the expression data of the panel of metabolic biomarkers in the biological subject is correlated with the one or more reference metabolic biomarker panels by the computer to be indicative of disease and where the diagnostic accuracy is at least 90%. In further embodiments, the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline. In further embodiments, the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims.
- The features and advantages of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:
-
FIGS. 1A and 1B show metabolic profiling of plasma of PAH patients (n=11) and comparison with diabetes mellitus (DM, n=12) and left heart disease (Heart, n=11) patients. These data indicate significantly (p<0.05) altered metabolites in PAH versus Heart and PAH versus DM analysis.FIG. 1A shows heat maps andFIG. 1B shows principal component analysis (PCA) showing the clustering of the PAH group that could differentiate PAH patients from DM and Heart by circulating metabolites. -
FIG. 2A shows an analysis of two independent runs of plasma metabolites from PAH patients (n=11). Circles indicate the same patient in two experiments. Data showed good reproducibility. -
FIG. 2B shows a comparison of PAH patients (n=11) with diabetes mellitus (DM, n=12) and left heart disease (Heart, n=11) patients altogether with only eleven selected metabolites that give maximal separation of the clustering analysis. Ellipses indicate the area of 0.95 probability that metabolic profiling of the patient from the same group will be inside an ellipse. Based on analysis of 11 preselected metabolites, the PAH group appears to be significantly (p<0.05) separated from either DM or Heart patients. -
FIG. 3 shows circulating metabolites distinguish PAH patients from other diseases.FIG. 3 shows principal component analysis (PCA) of Health and PAH cohorts. Profiling of circulating metabolites was focused on eleven metabolites that significantly distinguish PAH patients from the healthy subjects. Ellipses indicate 95% confidence. By monitoring the Panel #1 metabolites (Table 1), healthy individuals are efficiently separated from PAH patients (FIG. 3 ). Ellipses show 95% confidence that the next examined person will fall inside the ellipse corresponding to the diagnosis. Notably, the PAH cohort consisted of two geographical locations (the University of Colorado and University of Arizona cohorts), which confirm that patients' geographical affiliation does not affect the test outcome -
FIG. 4 shows early PAH detection using Panel #1 (Table 1).FIG. 4 shows a PCA in which there is an overlap between the mild PAH (mPAP 20-25 mmHg, diamonds), advanced PAH (mPAP>45 mmHg, cicles), and treatment naïve group (triangles). This result indicates that metabolically all groups are similar and could be efficiently identified regardless of the disease stage or treatment approach. Cohorts of patients were examined with early/mild PAH with borderline mean Pulmonary Arterial Pressure (mPAP=20-25 mmHg), with advanced PAH (mPAP>45 mmHg), and treatment naïve patients, who did not receive treatments. The data indicate that mild and advanced PAH were indistinguishable. Thus, Panel #1 (Table 1) can diagnose PAH at the early stage with the same accuracy as in advanced PAH. This highlights the test capability to effectively evaluate PAH's mildest form (mPAP=20-25 mmHg), which has recently been considered the upper limit of the normal. Furthermore, the complex therapeutic scheme, which could vary from patient to patient, does not affect the ability of Panel #1 (Table 1) to diagnose the PAH since we see no differences between the treated and treatment-naïve patient groups. -
FIG. 5A-5B shows that machine learning/deep learning (ML/DL) algorithms can be used for metabolic pattern recognition. Machine learning algorithms are robust tools for recognizing a variety of patterns, including metabolic panels. The preliminary studies tested whether ML/DL classification approaches can be trained to label “unknown” samples with high precision. For this purpose, Panel #1 was used for the logistic regression algorithm training. After training, the algorithm randomly picked a sample and marked it as unknown (cross-validation), and predicted the disease. The confusion matrix shown inFIG. 5A indicates ML predictions for PAH patients vs. Healthy controls indication—100% accuracy.FIG. 5B shows the confusion matrix for predicting diabetics (d), left heart disease (h), and pulmonary hypertension (p), and Σ- indicates the number of “unknown samples” attempts. Based on these data, the ML/DL approach shows no confusion in diagnosing PAH patients using panels of circulating metabolites. - Any methods, devices and materials similar or equivalent to those described herein can be used in the practice of this invention. The following definitions are provided to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise. Headings used herein are for organizational purposes only and in no way limit the invention described herein.
- As used herein, the term “pulmonary hypertension (PH) refers to a disease characterized by an increase of blood pressure in the pulmonary artery. Pulmonary hypertension is determined as mean pulmonary artery pressure (mPAP) 20 mm Hg at rest measured by right heart catheterization. The increase in pulmonary arterial blood pressure may lead to shortness of breath, dizziness, fainting, leg swelling, and other symptoms. Pulmonary hypertension can be a severe disease with a markedly decreased exercise tolerance. The disease may be hereditary. According to the most recent classification of the World Health Organization (WHO), pulmonary hypertension can be one of the following different types: pulmonary arterial hypertension (PAH), pulmonary hypertension due to left heart disease, pulmonary hypertension due to lung disease and/or hypoxia (e. g. pulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) or PH due to interstitial lung disease (ILD), chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary hypertension with unclear multifactorial mechanisms (group 5).
- As used herein, the term “pulmonary arterial hypertension (PAH)” refers to a disease characterized by an increase of blood pressure in the pulmonary artery where underlying causes for example left heart disease, lung disease, CTEPH, and
group 5 diseases have been excluded. Pulmonary arterial hypertension includes a number of subgroups. In particular, it encompasses idiopathic pulmonary arterial hypertension (IPAH), hereditary PAH, and associated PAH (APAH) which may be associated to drug or toxins, connective tissue diseases, HIV infection, portal hypertension. - As used herein, PAH and PH may be used interchangeably.
- As used herein, “administering” and the like refer to the act of physically delivering a composition or other therapy (e.g. a treatment for PAH) described herein into a subject by such routes as oral, mucosal, topical, transdermal, suppository, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration. Parenteral administration includes intravenous, intramuscular, intra-arterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. When a disease, disorder or condition, or a symptom thereof, is being treated, administration of the substance typically occurs after the onset of disease, disorder or condition or symptoms thereof. When a disease, disorder or condition, or symptoms thereof, are being prevented, administration of the substance typically occurs before the onset of the disease, disorder or condition or symptoms thereof.
- As used herein, the terms “subject” and “patient” are used interchangeably. As used herein, a subject can be an animal (amphibian, reptile, avian, fish, or mammal) such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) or a primate (e.g., monkey, ape and human). In specific embodiments, the subject is a human. In one embodiment, the subject is a mammal (e.g., a human, a dog) having a disease, disorder or condition described herein. In another embodiment, the subject is a mammal (e.g., a human, a dog) at risk of developing a disease, disorder or condition described herein. In certain instances, the term patient refers to a human under medical care or animals under veterinary care.
- As used herein, the terms “normal subject or “healthy subject” or “control subject” may be used interchangeably and refers to a subject with no underlying chronic or acute disease conditions.
- The terms “treating” or “treatment” refer to any indicia of success or amelioration of the progression, severity, and/or duration of a disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a patient's physical or mental well-being. Common treatments for PAH comprise administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and/or balloon angioplasty.
- The term “effective amount” as used herein refers to the amount of a therapy or medication (e.g., treatment for PAH) which is sufficient to reduce and/or ameliorate the severity and/or duration of a given disease, disorder or condition and/or a symptom related thereto. This term also encompasses an amount necessary for the reduction or amelioration of the advancement or progression of a given disease (e.g., PAH), disorder or condition, reduction or amelioration of the recurrence, development or onset of a given disease, disorder or condition, and/or to improve or enhance the prophylactic or therapeutic effect(s) of another therapy. In some embodiments, “effective amount” as used herein also refers to the amount of therapy provided herein to achieve a specified result.
- As used herein, and unless otherwise specified, the term “therapeutically effective amount” of a drug or intervention is an amount sufficient enough to provide a therapeutic benefit in the treatment or management of a PAH, or to delay or minimize one or more symptoms associated with the presence of PAH. A therapeutically effective amount of a treatment for PAH, means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of PAH. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of PAH, or enhances the therapeutic efficacy of another therapeutic agent.
- A therapy is any protocol, method and/or agent that can be used in the prevention, management, treatment and/or amelioration of a given disease, disorder or condition. In certain embodiments, the terms “therapies” and “therapy” refer to a drug therapy, biological therapy, supportive therapy, radiation therapy, exercise therapy, and/or other therapies useful in the prevention, management, treatment and/or amelioration of a given disease, disorder or condition known to one of skill in the art such as medical personnel. Common therapies for PAH comprise administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and/or balloon angioplasty.
- Referring now to
FIGS. 1A, 1B, 2A, 2B, 3, 4, 5A and 5B the present invention features diagnostic, treatment and monitoring methods, and kits for PAH that allow for early diagnosis as well as monitoring of PAH and distinction of PAH from DM and/or left heart disease. The present invention utilizes targeted metabolomics to determine levels of metabolites, which are measured in a biological sample (e.g., plasma, urine, serum) using standard analytical techniques including GC-TOF mass spectrometry. The metabolites comprise oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, uridine diphosphate (UDP)-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline. The metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid. A metabolic profile is then determined based on the measured level of at least one metabolite. The profile is a metabolic fingerprint that distinguishes patients with PAH as compared to those with DM and/or left heart disease. This fingerprint can be used for diagnosis, monitoring, guiding treatment for patients having or suspected of having PAH. - The present invention features a computer-implemented method for diagnosing a subject with a disease. In some embodiments, the method comprises inputting expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject. In other embodiments, the method comprises determining whether expression of the metabolic biomarkers in the biological sample obtained from the subject is indicative of a disease using a computer system programmed with a trained machine learning classifier for distinguishing subjects with different diseases and without disease. In some embodiments, the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having disease and from control subjects that do not have disease. In some embodiments, the method comprises diagnosing the subject. In some embodiments, the expression data of the panel of metabolic biomarkers in the biological sample obtained from the subject is correlated by the computer system to be indicative of disease; and where the diagnostic accuracy is at least 90%. In other embodiments, the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, oxoproline. In further embodiments, the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- In some embodiments, the expression data of the panel of metabolic biomarkers is determined using standard clinical chemistry techniques, protein analytic techniques, nucleic acid techniques, and/or analytical techniques suitable for metabolite analysis (e.g., Gas chromatography—time of flight mass spectrometry (GC-TOF) mass spectrometry, liquid chromatography mass spectrometry (LCMS), Nuclear magnetic resonance (NMR)).
- In some embodiments, the trained machine learning classifiers are the machine learning/deep learning algorithms including logistic regression, neural network, and other algorithms. As used herein, “a machine learning classifier” utilizes some training data to train algorithms to predict the class (a disease) with given input variables (expression data of metabolic biomarkers).
- In some embodiments the present invention may include a processor in communication with various elements of hardware. In some embodiments, the processor includes one or more processors configured to implement a set of instructions corresponding to any of the methods disclosed herein. In other embodiments, the processor can be configured to implement a set of instructions (stored in memory of hardware or sub-system) to provide a correlation between the expression data and a particular disease. In other embodiments, a sub-system can include hardware and software capable of facilitating the processing of data generated by hardware, in conjunction with, or as a substitute for, the processing that is normally handled by the processor.
- In some embodiments, the diagnostic accuracy of the computer system is 100%. In some embodiments, the diagnostic accuracy of the computer system is at least 99%. In some embodiments, the diagnostic accuracy of the computer system is at least 98%. In some embodiments, the diagnostic accuracy of the computer system is at least 95%. In some embodiments, the diagnostic accuracy of the computer system is at least 90%. In some embodiments, the diagnostic accuracy of the computer system is 85%. In some embodiments, the diagnostic accuracy of the computer system is at least 80%.
- In other embodiments, the present invention utilizes metabolites comprising carbohydrates, amino acids, fatty acids and/or nucleotides and their derivatives.
- In some embodiments, the present invention is for a patient who is asymptomatic or symptomatic for pulmonary hypertension, diabetes mellitus, heart disease, lung diseases, chronic liver, kidney diseases, cancers and other chronic or acute conditions characterized with metabolic changes in the mitochondria, alterations in glycolytic pathways, protein biosynthesis/oxidation, fatty acids biosynthesis/oxidations, etc. In preferred embodiments, the biological sample is easily obtained from the patient and can comprise plasma, serum, urine, lung fluids, lavage, etc.
- In some embodiments, the metabolites are measured throughout time in biological samples obtained from subjects longitudinally throughout time. Non-limiting examples of longitudinal timing points comprise 1) an initial time comprising at time of no symptoms, at time of diagnosis, or at initial presentation of symptoms; 2) about weekly intervals post initial time; 3) about monthly intervals post initial time; and/or 4) about yearly intervals.
- In some embodiment, the disease comprises pulmonary arterial hypertension (PAH), Diabetes Mellitus (DM), left heart disease, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), head and neck cancer, thyroid cancer or colon cancer. In some embodiments, the method is able to differentiate between PAH, DM, and left heart disease. In other embodiments, the metabolic biomarker panel is distinctly different in subjects with pulmonary arterial hypertension (PAH) compared to subjects with Diabetes Mellitus (DM) or left heart disease.
- In some embodiments, the method may be used for pre-screening the subject either to identify pulmonary arterial hypertension (PAH) at the asymptomatic stage or to minimize the time for PAH diagnosis after the initial symptom onset. In other embodiments, the method is used for determining the severity of PAH in the patient. In further embodiments, the method discriminates between pulmonary arterial hypertension (PAH) and classical metabolic disorders, including diabetes mellitus (DM), or left heart diseases. In other embodiments, the method is used in subjects with other diseases comprising cancer, lung diseases, and systemic hypertension. In further embodiments, the method is used to guide treatment and/or care management of the subject diagnosed with pulmonary arterial hypertension (PAH).
- In some embodiments, the subject does not display clinical symptoms (i.e., asymptomatic) or does display clinical symptoms (i.e., symptomatic) for pulmonary arterial hypertension (PAH), DM, left heart diseases, lung diseases, kidney and liver disease, cancers or other acute and chronic conditions characterized with metabolic changes, wherein symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- In some embodiments, a biological sample may comprise plasma, serum, or urine, obtained from the subject.
- The present invention may further feature a method of treating a subject with pulmonary arterial hypertension (PAH). In some embodiments, the method comprises determining the expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject. In some embodiments, the method comprises treating PAH in a subject identified as having differing levels of the panel of metabolic biomarkers when compared to the levels of said metabolic biomarkers in a normal subject. In other embodiments, the panel of metabolic biomarkers comprises oxalic acid, aminomalonate, pseudouridine, gluconic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid, glutamic acid, phosphate, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline. In further embodiments, the subject with PAH has a higher level of oxalic acid, aminomalonate, pseudouridine, gluconic acid, uric acid, UDP-glucuronic acid, aconitic acid, 2-deoxytetronic acid, myo-inositol, citric acid, glutamic acid, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, oxoproline than the normal subject. In other embodiments, the subject with PAH has a lower level of erythritol, fumaric acid, and phosphate than the normal subject.
- In some embodiments, the expression data of the panel of metabolic biomarkers is determined using standard clinical chemistry techniques, protein analytic techniques, nucleic acid techniques, and/or analytical techniques suitable for metabolite analysis (e.g., Gas chromatography—time of flight mass spectrometry (GC-TOF) mass spectrometry, liquid chromatography mass spectrometry (LCMS), Nuclear magnetic resonance (NMR)).
- In some embodiments, the method is used for determining the severity of PAH in the subject. In other embodiments, the subject does not display clinical symptoms (i.e., asymptomatic) or does display clinical symptoms (i.e., symptomatic) for pulmonary arterial hypertension (PAH), DM, left heart diseases, lung diseases, kidney and liver disease, cancers or other acute and chronic conditions characterized with metabolic changes, wherein symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations). In some embodiments, the method is used to guide treatment and/or care management of the subject diagnosed with pulmonary arterial hypertension (PAH).
- In some embodiments, the biological sample comprises plasma, serum, urine, obtained from the subject.
- In some embodiments, the treatment of pulmonary hypertension comprises administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and/or balloon angioplasty.
- The present invention may feature a non-transitory, computer-readable medium having computer executable instructions for causing a processor to execute a method for diagnosing a subject with a disease. In some embodiments, the method comprises determining whether expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is indicative of the disease using a trained machine learning classifier for distinguishing subjects with different diseases and without disease. In some embodiments, the machine learning classifier has been trained using expression data of a panel of metabolic biomarkers from subjects having the disease and from control subjects that do not have disease. In some embodiments, the method comprises diagnosing the subject if the expression data is correlated to be indicative of the disease. In some embodiments, the diagnostic accuracy is at least 90%. In other embodiments, the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline.
- The present invention may also feature a kit for diagnosing a subject with a disease. In some embodiments, the kit comprises one or more reference metabolic biomarker panels (see Table 1, 2, 3). In other embodiments, the kit comprises a non-transitory, computer-readable medium described herein. In some embodiments, expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject is inputted into a computer that executes the computer executable instructions of the non-transitory, computer-readable medium. In other embodiments, a subject is diagnosed with disease when the expression data of the panel of metabolic biomarkers in the biological subject is correlated with the one or more reference metabolic biomarker panels by the computer to be indicative of disease and where the diagnostic accuracy is at least 90%. In further embodiments, the panel of metabolic biomarkers comprises at least 5 metabolites selected from a group consisting of oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, UDP-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline. In further embodiments, the metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid.
- In some embodiments, the expression data of the panel of metabolic biomarkers is determined using standard clinical chemistry techniques, protein analytic techniques, nucleic acid techniques, and/or analytical techniques suitable for metabolite analysis (e.g., Gas chromatography—time of flight mass spectrometry (GC-TOF) mass spectrometry, liquid chromatography mass spectrometry (LCMS), Nuclear magnetic resonance (NMR)).
- In some embodiments, the metabolites are measured throughout time in biological samples obtained from subjects longitudinally throughout time. Non-limiting examples of longitudinal timing points comprise 1) an initial time comprising at time of no symptoms, at time of diagnosis, or at initial presentation of symptoms; 2) about weekly intervals post initial time; 3) about monthly intervals post initial time; and/or 4) about yearly intervals.
- In some embodiment, the disease comprises pulmonary arterial hypertension (PAH), Diabetes Mellitus (DM), left heart disease, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), head and neck cancer, thyroid cancer or colon cancer. In some embodiments, the method is able to differentiate between PAH, DM, and left heart disease. In other embodiments, the metabolic biomarker panel is distinctly different in subjects with pulmonary arterial hypertension (PAH) compared to subjects with Diabetes Mellitus (DM) or left heart disease.
- In some embodiments, the kit may be used for pre-screening the subject either to identify pulmonary arterial hypertension (PAH) at the asymptomatic stage or to minimize the time for PAH diagnosis after the initial symptom onset. In other embodiments, the kit is used for determining the severity of PAH in the patient. In further embodiments, the kit discriminates between pulmonary arterial hypertension (PAH) and classical metabolic disorders, including diabetes mellitus (DM), or left heart diseases. In other embodiments, the kit is used in subjects with other diseases comprising cancer, lung diseases, and systemic hypertension. In further embodiments, the method is used to guide treatment and/or care management of the subject diagnosed with pulmonary arterial hypertension (PAH).
- In some embodiments, the subject does not display clinical symptoms (i.e., asymptomatic) or does display clinical symptoms (i.e., symptomatic) for pulmonary arterial hypertension (PAH), DM, left heart diseases, lung diseases, kidney and liver disease, cancers or other acute and chronic conditions characterized with metabolic changes, wherein symptoms comprise, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- In other embodiments, the subject is asymptomatic or symptomatic for PAH, DM, left heart disease, wherein an asymptomatic patient does not display clinical symptoms of PAH, DM, left heart disease and asymptomatic patient displays clinical symptoms of PAH, DM, left heart disease comprising shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations).
- In other embodiments, the 36 metabolites (Table 1) comprise mitochondrial-derived metabolites, carbohydrates, metabolites of myo-inositol and its derivatives, and/or metabolites that are indicative of damage known to be directly associated with PAH or an altered gut microbiome, and/or metabolites associated with PAH pathogenesis. Non-limiting examples of mitochondrial-derived metabolites comprise tricarboxylic acid (TCA) metabolites and their derivatives, including oxalic acid.
- In preferred embodiments, the metabolomic biomarker panel is distinctly different in patients with PAH compared to diabetic patients or patients with left heart diseases. In other embodiments, the tools, methods, and kits described herein using the metabolomic profile or fingerprint is used for 1) pre-screening of patients either to identify PAH at the asymptomatic stage or to minimize the time for PAH diagnosis after the initial symptom onset; 2) determining the severity of PAH in a patient; 3) discriminating between PAH and classical metabolic disorders (e.g., DM) or left heart diseases that often mimic the symptoms of right heart disease; 4) patient cohorts with other diseases comprising cancer, lung diseases, and systemic hypertension; and 5) treatment and/or care management of a patient suspected of having or has PAH.
- In some embodiments, 36 unique plasma metabolites or markers differentiate patients with PAH, DM, and left heart diseases. Of the 36 metabolites that are significantly altered in PAH as compared to diabetes mellitus and left heart diseases.
- In some embodiments, symptomatic patients comprise patients with clinical symptoms of pulmonary stress, shortness of breath, first noticeable with exercise, but as the disease progresses, even during rest; feeling tired (fatigue); swelling in the feet, legs, belly or neck; chest pain; and/or heart pounding (palpitations). In other embodiments, asymptomatic patients do not overtly display the aforementioned clinical symptoms.
-
TABLE 2 Metabolites that are significantly different between pulmonary hypertension, COPD and ILD cohorts. Fold ILD p-value Fold COPD p-value adenosine-5-monophosphate 0.322291 0.000924 0.38641893 0.008464 3-phenyllactic acid 0.492135 0.001583 1.09598575 0.659976 pyrophosphate 0.503944 0.002213 0.5896616 0.009202 uric acid 1.938433 0.007498 1.52389566 0.042332 maltotriose 0.367153 0.012609 0.41858632 0.020487 glucose-1-phosphate 1.811182 0.015604 1.17356234 0.366675 myristic acid 1.945851 0.025099 1.70557262 0.043406 docosahexaenoic acid 2.030901 0.040692 1.53074952 0.136565 aspartic acid 0.837658 0.25527 0.6776052 0.010062 myo-inositol 0.853897 0.26947 0.69733062 0.012334 tocopherol gamma- 1.296965 0.278877 1.88540879 0.029407 5-methoxytryptamine 0.669009 0.441173 1.94907759 0.414254 arachidic acid 1.099185 0.474805 1.3291263 0.049677 -
TABLE 3 Metabolites that are significantly different in colon, thyroid, and Head and neck cancer cohort. p-value p-value p-value Head& Colon Thyroid Neck cystine 1.65E−06 9.19E−03 2.73E−02 adenosine-5-monophosphate 2.25E−05 7.45E−01 3.88E−02 adipic acid 2.34E−05 2.28E−01 7.00E−01 creatinine 1.45E−04 6.22E−02 6.99E−01 3-hydroxybutyric acid 1.59E−04 8.00E−02 6.32E−02 cholesterone 4.77E−04 2.33E−05 7.15E−06 2,4-diaminobutyric acid 1.23E−03 7.46E−03 1.06E−04 aminomalonate 4.14E−03 4.99E−08 9.27E−10 oxalic acid 1.01E−02 4.80E−10 7.24E−08 3-aminoisobutyric acid 2.09E−02 8.13E−02 9.62E−01 N-acetylornithine 4.67E−01 2.47E−08 3.76E−10 - The present invention also features an in vitro method for diagnosing, monitoring, or treating a patient suffering pulmonary arterial hypertension (PAH) in a patient. In preferred embodiments, the method comprises first obtaining a biological sample from the patient. Non-limiting examples of a biological sample comprise an easily obtained sample from a patient, e.g., plasma, serum, blood, and/or urine. Targeted metabolomics is then performed to determine levels of metabolites, which are measured in the biological sample using standard analytical techniques including GC-TOF mass spectrometry. The metabolites comprise oxalic acid, aminomalonate, pseudouridine, gluconic acid, isothreonic acid, 4-hydroxyphenylacetic acid, erythritol, uric acid, uridine diphosphate (UDP)-glucuronic acid, fumaric acid, focuse, aconitic acid, 2-deoxytetronic acid, pantothenic acid, indole-3-acetate, myo-inositol, 2-hydroxyvaleric acid, citric acid, ribonic acid, glycine, glutamic acid, creatinine, glucuronic acid, phosphate, indole-3-lactate, urea, 2-hydroxyglutaric acid, tryptophan, tyrosine, glutamine, lysine, histidine, N-acetylornithine, 2-hydroxybutanoic acid, alpha-ketoglutarate, and oxoproline. The metabolites may further comprise adenosine-5-monophosphate, 3-phenyllactic acid, pyrophosphate, maltotriose, glucose-1-phosphate, myristic acid, docosahexaenoic acid, aspartic acid, tocopherol gamma, 5-methoxytryptamine, arachidic acid, cystine, adipic acid, 3-hydroxybutyric acid, cholesterone, 2,4-diaminobutyric acid, and 3-aminoisobutyric acid. In some embodiments, a metabolic profile is then determined based on the measured level of at least five metabolites. In some embodiments, the profile is a metabolic fingerprint that distinguishes patients with PAH as compared to those with Diabetes Mellitus (DM) and/or left heart disease.
- In some embodiments, the patient is then diagnosed for PAH based on the metabolic profiled fingerprint that distinguishes patients with PAH as compared to those with Diabetes Mellitus (DM) and/or left heart disease. In other embodiments, the patient is then monitored throughout time for reduction, progression, or stable disease of PAH based on the metabolic profiled fingerprint that distinguishes patients with PAH as compared to those with DM and/or left heart disease. Non-limiting examples of longitudinal timepoints to measure the metabolites comprise at initial assessment for PAH, presentation of initial symptoms of PAH or diagnosis PAH, and then weekly, monthly, and/or yearly timepoints. In further embodiments, if the patient is diagnosed for PAH based on the metabolic profiled fingerprint that distinguishes patients with PAH as compared to those with Diabetes Mellitus (DM) and/or left heart disease. An effective amount of a therapeutic treatment is then administered based on the fingerprint to effectively treat the patient with PAH. The treatment of pulmonary hypertension/PAH may be selected from the group consisting of the administration of a drug, surgery, transplantation, exercise training, physical rehabilitation, and balloon angioplasty.
- In some embodiments, the present invention includes a computer system that can execute the methods for diagnosing a disease as described herein. In some embodiments, the invention employs a computer device or computer-implemented method having one or more processors and at least one memory, the at least one memory storing non-transitory computer-readable instructions for execution by the one or more processors to cause the one or more processors to execute instructions (or stored data) in one or more modules. Alternatively, the instructions may be stored in a non-transitory computer-readable medium or computer-usable medium. In some embodiments, a computer system can include a desktop computer, a laptop computer, a tablet, or the like and can include digital electronic circuitry, firmware, hardware, memory, a computer storage medium, a computer program, a processor (including a programmed processor), or the like. The computing system may include a desktop computer with a screen and a tower.
- The term “processor” encompasses all kinds of apparatus, devices, and machines for processing data, including by way of example a programmable microprocessor, a computer, a system on a chip, or multiple ones, or combinations, of the foregoing. The apparatus can include special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application-specific integrated circuit). The apparatus also can include, in addition to hardware, code that creates an execution environment for the computer program in question, e.g., code that constitutes processor firmware, a protocol stack, a database management system, an operating system, a cross-platform runtime environment, a virtual machine, or a combination of one or more of them. The apparatus and execution environment can realize various different computing model infrastructures, such as web services, distributed computing and grid computing infrastructures. The processor may include one or more processors of any type, such as central processing units (CPUs), graphics processing units (GPUs), special-purpose signal or image processors, field-programmable gate arrays (FPGAs), tensor processing units (TPUs), and so forth.
- A computer program (also known as a program, software, software application, script, or code) can be written in any form of programming language, including compiled or interpreted languages, declarative or procedural languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, object, or other unit suitable for use in a computing environment. A computer program may, but need not, correspond to a file in a file system. A program can be stored in a portion of a file that holds other programs or data (e.g., one or more scripts stored in a markup language document), in a single file dedicated to the program in question, or in multiple coordinated files (e.g., files that store one or more modules, subprograms, or portions of code). A computer program can be deployed to be executed on one computer or on multiple computers that are located at one site or distributed across multiple sites and interconnected by a communication network.
- Embodiments of the subject matter and the operations described herein can be implemented in digital electronic circuitry, or in computer software, firmware, or hardware, including the structures disclosed in this specification and their structural equivalents, or in combinations of one or more of them. Embodiments described in this specification can be implemented as one or more computer programs, i.e., one or more modules of computer program instructions, encoded on computer storage medium for execution by, or to control the operation of, data processing apparatus. Any of the modules described herein may include logic that is executed by the processor(s). “Logic,” as used herein, refers to any information having the form of instruction signals and/or data that may be applied to affect the operation of a processor. Software is an example of logic. Logic may be formed from signals stored on a computer-readable medium such as memory that, in an exemplary embodiment, may be a random access memory (RAM), read-only memories (ROM), erasable/electrically erasable programmable read-only memories (EPROMS/EEPROMS), flash memories, etc. Logic may also comprise digital and/or analog hardware circuits, for example, hardware circuits comprising logical AND, OR, XOR, NAND, NOR, and other logical operations. Logic: may be formed from combinations of software and hardware. On a network, logic may be programmed on a server, or a complex of servers. A particular logic unit is not limited to a single logical location on the network. Moreover, the modules need not be executed in any specific order. Each module may call another module when needed to be executed.
- A computer storage medium can be, or can be included in, a computer-readable storage device, a computer-readable storage substrate, a random or serial access memory array or device, or a combination of one or more of them. Moreover, while a computer storage medium is not a propagated signal, a computer storage medium can be a source or destination of computer program instructions encoded in an artificially generated propagated signal. The computer storage medium can also be, or can be included in, one or more separate physical components or media (e.g., multiple CDs, disks, or other storage devices). The operations described in this specification can be implemented as operations performed by a data processing apparatus on data stored on one or more computer-readable storage devices or received from other sources.
- Program code embodied on a computer readable medium may be transmitted using any appropriate medium, including but not limited to wireless, wireline, optical fiber cable, R.F, etc., or any suitable combination of the foregoing. Computer program code for carrying out operations for aspects of the present disclosure may be written in any combination of one or more programming languages, including an object oriented programming language such as Java, Smalitalk, C++ or the like and conventional procedural programming languages, such as the “C” programming language or similar programming languages. The program code may execute entirely on the user's computer, partly on the user's computer, as a stand-alone software package, partly on the user's computer and partly on a remote computer or entirely on the remote computer or server. In the latter scenario, the remote computer may be connected to the user's computer through any type of network, including a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider).
- The processes and logic flows described in this specification can be performed by one or more programmable processors executing one or more computer programs to perform actions by operating on input data and generating output. The processes and logic flows can also be performed by, and apparatus can also be implemented as, special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application-specific integrated circuit).
- Processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processors of any kind of digital computer. Generally, a processor will receive instructions and data from a read-only memory or a random access memory or both. The essential elements of a computer are a processor for performing actions in accordance with instructions and one or more memory devices for storing instructions and data. Generally, a computer will also include, or be operatively coupled to receive data from or transfer data to, or both, one or more mass storage devices for storing data, e.g., magnetic, magneto-optical disks, or optical disks.
- However, a computer need not have such devices. Moreover, a computer can be embedded in another device, e.g., a mobile telephone, a personal digital assistant (PDA), a mobile audio or video player, a game console, a Global Positioning System (GPS) receiver, or a portable storage device (e.g., a universal serial bus (USB) flash drive), to name just a few. Devices suitable for storing computer program instructions and data include all forms of non-volatile memory, media and memory devices, including by way of example semiconductor memory devices, e.g., EPROM, EEPROM, and flash memory devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks. The processor and the memory can be supplemented by, or incorporated in, special purpose logic circuitry.
- One or more computing devices such as desktop computers, laptop computers, tablets, smartphones, servers, application-specific computing devices, or any other type(s) of electronic device(s) may be capable of performing the techniques and operations described herein. In some embodiments, the system may be implemented as a single device. In other embodiments, the system may be implemented as a combination of two or more devices together. For example, the system may include one or more server computers and a one or more client computers communicatively coupled to each other via one or more local-area networks and/or wide-area networks such as the Internet.
- Computers typically include known components, such as a processor, an operating system, system memory, memory storage devices, input-output controllers, input-output devices, and display devices. It will also be understood by those of ordinary skill in the relevant art that there are many possible configurations and components of a computer and may also include cache memory, a data backup unit, and many other devices. To provide for interaction with a user, embodiments of the subject matter described in this specification can be implemented on a computer having a display device, e.g., an LCD (liquid crystal display). LED (light emitting diode) display, or OLED (organic light emitting diode) display, for displaying information to the user. Examples of input devices include a keyboard, cursor control devices (e.g., a mouse or a trackball), a microphone, a scanner, and so forth, wherein the user can provide input to the computer. Other kinds of devices can be used to provide for interaction with a user as well; for example, feedback provided to the user can be in any form of sensory feedback, e.g., visual feedback, auditory feedback, or tactile feedback; and input from the user can be received in any form, including acoustic, speech, or tactile input. Examples of output devices include a display device (e.g., a monitor or projector), speakers, a printer, a network card, and so forth. Display devices may include display devices that provide visual information, this information typically may be logically and/or physically organized as an array of pixels. In addition, a computer can interact with a user by sending documents to and receiving documents from a device that is used by the user; for example, by sending web pages to a web browser on a user's client device in response to requests received from the web browser.
- An interface controller may also be included that may comprise any of a variety of known or future software programs for providing input and output interfaces. For example, interfaces may include what are generally referred to as “Graphical User Interfaces” (often referred to as GUI's) that provide one or more graphical representations to a user. Interfaces are typically enabled to accept user inputs using means of selection or input known to those of ordinary skill in the related art. In some implementations, the interface may be a touch screen that can be used to display information and receive input from a user. In the same or alternative embodiments, applications on a computer may employ an interface that includes what are referred to as “command line interfaces” (often referred to as CLI's). CLI's typically provide a text based interaction between an application and a user. Typically, command line interfaces present output and receive input as lines of text through display devices. For example, some implementations may include what are referred to as a “shell” such as Unix Shells known to those of ordinary skill in the related art, or Microsoft Windows Powershell that employs object-oriented type programming architectures such as the Microsoft .NET framework.
- Those of ordinary skill in the related art will appreciate that interfaces may include one or more GUI's, CLI's or a combination thereof. A processor may include a commercially available processor such as a Celeron, Core, or Pentium processor made by Intel Corporation, a SPARC processor made by Sun Microsystems, an Athlon, Sempron, Phenom, Ryzen or Opteron processor made by AMD Corporation, or it may be one of other processors that are or will become available. Some embodiments of a processor may include a multi-core processor and/or be enabled to employ parallel processing technology in a single or multi-core configuration. For example, a multi-core architecture typically comprises two or more processor “execution cores”. Each execution core may perform as an independent processor that enables parallel execution of multiple threads. In addition, those of ordinary skill in the related will appreciate that a processor may be configured in what is generally referred to as 32 or 64 bit architectures, or other architectural configurations now known or that may be developed in the future.
- A processor typically executes an operating system, which may be, for example, a Windows type operating system from the Microsoft Corporation; the Mac OS X op-crating system from Apple Computer Corp.; a Unix or Linux-type operating system available from many vendors or what is referred to as an open source; another or a future operating system; or some combination thereof. An operating system interfaces with firmware and hardware in a well-known manner, and facilitates the processor in coordinating and executing the functions of various computer programs that may be written in a variety of programming languages. An operating system, typically in cooperation with a processor, coordinates and executes functions of the other components of a computer. An operating system also provides scheduling, input-output control, file and data management, memory management, and communication control and related services, all in accordance with known techniques.
- Embodiments of the subject matter described in this specification can be implemented in a computing system that includes a back-end component, e.g., as a data server, or that includes a middleware component, e.g., an application server, or that includes a front-end component, e.g., a client computer having a graphical user interface or a Web browser through which a user can interact with an implementation of the subject matter described in this specification, or any combination of one or more such back-end, middleware, or front-end components. The components of the system can be interconnected by any form or medium of digital data communication, e.g., a communication network. Examples of communication networks include a local area network (“LAN”) and a wide area network (“WAN”), an inter-network (e.g., the Internet), and peer-to-peer networks (e.g., ad hoc peer-to-peer networks). For example, the network can include one or more local area networks. The computing system can include any number of clients and servers. A client and server are generally remote from each other and typically interact through a communication network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other. In some embodiments, a server transmits data (e.g., an HTML page) to a client device (e.g., for purposes of displaying data to and receiving user input from a user interacting with the client device). Data generated at the client device (e.g., a result of the user interaction) can be received from the client device at the server.
- Also, a computer may include one or more library files, experiment data files, and an internet client stored in system memory. For example, experiment data could include data related to one or more experiments or assays, such as detected signal values, or other values associated with the biomarker expression data. Additionally, an internet client may include an application enabled to access a remote service on another computer using a network and may for instance comprise what are generally referred to as “Web Browsers”, In the present example, some commonly employed web browsers include Microsoft Internet Explorer available from Microsoft Corporation, Nilozilla Firefox from the Mozlla Corporation, Safari from Apple Computer Corp., Google Chrome from the Google Corporation, or other type of web browser currently known in the art or to be developed in the future. Also, in the same or other embodiments an Internet client may include, or could be an element of, specialized software applications enabled to access remote information via a network such as a data processing application for biological applications.
- A network may include one or more of the various types of networks known to those of ordinary skill in the art. For example, a network may include a local or wide area network that may employ what is commonly referred to as a TCP/IP protocol suite to communicate. A network may include a network comprising a worldwide system of interconnected computer networks that is commonly referred to as the internet, or could also include various intranet architectures. Those of ordinary skill in the related arts will also appreciate that some users in networked environments may prefer to employ what are generally referred to as “firewalls” (also sometimes referred to as Packet Filters, or Border Protection De-vices) to control information traffic to and from hardware and/or software systems. For example, firewalls may comprise hardware or software elements or some combination thereof and are typically designed to enforce security policies put in place by users, such as for instance network administrators, etc.
- When executed, instructions (which may be stored in the memory) cause at least one of the processors of the computer system to receive an input, which is expression data of a panel of metabolic biomarkers in a biological sample obtained from the subject i. Once the necessary inputs are provided, a module is then executed to derive object features and context features and to calculate object feature metrics and context feature metrics. The object feature metrics and context feature metrics are provided to a trained end classifier, which classifies the object and provides an output to the user. The output may be to a display, a memory, or any other means suitable in the art.
- The following are non-limiting examples of the present invention. It is to be understood that said examples are not intended to limit the present invention in any way. Equivalents or substitutes are within the scope of the present invention.
- The plasma metabolic profiles were examined in patients with idiopathic PAH, patients with
type 2 diabetes mellitus (DM) (University of Arizona (UA) Center for Disparities in Diabetes, Obesity, and Metabolism) and patients with left heart diseases (Heart) (UA biobank). Groups were matched for age (mean±STD): 41.1±15.7; 41.8±13.7; 50.2±10.9; and sex female/male (%): 81.8/18.1; 83.3/16.7; 72.7/27.3; for PAH, DM and Heart, respectively. - Targeted metabolomic analysis was used to quantify primary plasma metabolites, including carbohydrates, amino acids, and nucleotides by GC-TOF mass spectrometry. Two runs of profiling were acquired separately, PAH versus DM and PAH versus Heart. In the DM/PAH run, from the 172 metabolites detected, 84 metabolites were significantly altered (p<0.05). A comparison of PAH and Heart groups showed 76 significantly changed metabolites among 158 that were identified. Heat maps in
FIG. 1A show characteristic clustering of PAH group, distinguishing them from DM and Heart patients. Principal component analysis (PCA) of significantly changed metabolites showed clear separation of PAH sub-population from DM and Heart patients (FIG. 1B ). The results of this analysis indicate that the plasma metabolomics profile is distinctly different in patients with PAH compared to diabetic patients or patients with left heart diseases. Therefore, the plasma metabolome has a strong potential to serve as a diagnostic tool. - Moreover, 32 unique metabolites that are significantly altered in PAH patients compared to either diabetics or left heart patients can be used as a fingerprint for PAH. These unique metabolites can be classified into five major groups.
- The primary group of metabolites consists of mitochondrial-derived metabolites, including tricarboxylic acid (TCA) metabolites and their derivatives. Oxalic acid, the product of oxaloacetate decomposition, was increased over 20-fold in PAH. These changes may indicate undergoing anaplerotic reactions resulting in an accumulation of oxaloacetate, as well as other TCA metabolites.
- The next largest group of metabolites consists of carbohydrates. This could be an indication of altered glycolysis due to the metabolic shift associated with PAH pathogenesis. Vascular remodeling in PAH could be the main reason for a decreased level of circulating amino acids, the primary building blocks of proteins that are highly consumed by proliferating cells.
- The next important group of metabolites that distinguish PAH patients from other patient cohorts related to myo-inositol and its derivatives. Myo-inositol was recently shown to play an important role in proliferative signaling in PAH.
- The last two groups of metabolites contain metabolites that are indicative of damage known to be directly associated with PAH, or an altered gut microbiome, which has also been implemented/implicated in PAH pathogenesis.
- Although the analysis of PAH samples vs. DM or Heart cohorts were assessed in two different runs, a very robust reproducibility of the metabolic data is shown in
FIG. 2A , upper panel). The two experiments were then combined using the PAH group as a reference point and comparing all three patients' cohorts together (FIG. 2B , lower panel). - A metabolite optimization approach and regression analysis identified the minimal number of metabolites sufficient for a significant separation of PAH group from DM and Heart. In the lower panel of
FIG. 2B , eleven metabolites were used to distinguish PAH samples from other patients. Ellipses showed the area of 0.95 probability that patients from the specific group will fall inside the ellipse area. This analysis indicates that although there is some small intersection between DM and Heart groups, PAH patients were well resolved from both diseases. - The panel of eleven metabolites comprises oxalic acid, pseudouridine, gluconic acid, fumaric acid, UDP-glucuronic acid, aconitic acid, erythritol, 2-deoxytetronic acid, glutamic acid, inorganic phosphate, and 2-hydroxyglutaric acid and can be used for the pre-screening of patients either to identify PAH at the asymptomatic stage or help to minimize the time for PAH diagnosis after the initial symptom onset reported to be currently 47.1±34.2 months.
- In summary, the present invention features application or use of metabolic profiling as a new diagnostic method and provides subsequent research with a specific set of preselected metabolites that could serve as a fingerprint of PAH and/or discerning the pathogenesis of PAH.
- As used herein, the term “about” refers to plus or minus 10% of the referenced number.
- Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims. Therefore, the scope of the invention is only to be limited by the following claims. In some embodiments, the figures presented in this patent application are drawn to scale, including the angles, ratios of dimensions, etc. In some embodiments, the figures are representative only and the claims are not limited by the dimensions of the figures. In some embodiments, descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting essentially of” or “consisting of”, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting essentially of” or “consisting of” is met.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/792,902 US20230073725A1 (en) | 2020-01-14 | 2021-01-14 | Metabolite biomarker profile and method of use to diagnose pulmonary arterial hypertension (pah) |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062960951P | 2020-01-14 | 2020-01-14 | |
PCT/US2021/013405 WO2021146401A1 (en) | 2020-01-14 | 2021-01-14 | Metabolite biomarker profile and method of use to diagnose pulmonary arterial hypertension (pah) |
US17/792,902 US20230073725A1 (en) | 2020-01-14 | 2021-01-14 | Metabolite biomarker profile and method of use to diagnose pulmonary arterial hypertension (pah) |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230073725A1 true US20230073725A1 (en) | 2023-03-09 |
Family
ID=76864635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/792,902 Pending US20230073725A1 (en) | 2020-01-14 | 2021-01-14 | Metabolite biomarker profile and method of use to diagnose pulmonary arterial hypertension (pah) |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230073725A1 (en) |
EP (1) | EP4090973A4 (en) |
WO (1) | WO2021146401A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114636774A (en) * | 2022-04-22 | 2022-06-17 | 苏州市疾病预防控制中心 | Biological metabolism marker composition for predicting risk of juvenile hypertension |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115701540A (en) * | 2021-08-02 | 2023-02-10 | 中国科学院深圳先进技术研究院 | Marker, detection method and kit for evaluating heart damage of schizophrenia patient |
US11754536B2 (en) | 2021-11-01 | 2023-09-12 | Matterworks Inc | Methods and compositions for analyte quantification |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011247869A (en) * | 2010-04-27 | 2011-12-08 | Kobe Univ | Inspection method of specific disease using metabolome analysis method |
US20150072360A1 (en) * | 2011-12-14 | 2015-03-12 | The Johns Hopkins University | Biomarkers of pulmonary hypertension |
US20190310269A1 (en) * | 2018-04-04 | 2019-10-10 | Human Longevity, Inc. | Systems and methods for measuring obesity using metabolome analysis |
-
2021
- 2021-01-14 WO PCT/US2021/013405 patent/WO2021146401A1/en unknown
- 2021-01-14 EP EP21741118.0A patent/EP4090973A4/en active Pending
- 2021-01-14 US US17/792,902 patent/US20230073725A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114636774A (en) * | 2022-04-22 | 2022-06-17 | 苏州市疾病预防控制中心 | Biological metabolism marker composition for predicting risk of juvenile hypertension |
Also Published As
Publication number | Publication date |
---|---|
EP4090973A1 (en) | 2022-11-23 |
EP4090973A4 (en) | 2024-05-29 |
WO2021146401A1 (en) | 2021-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230073725A1 (en) | Metabolite biomarker profile and method of use to diagnose pulmonary arterial hypertension (pah) | |
Choi et al. | Machine learning for the prediction of new-onset diabetes mellitus during 5-year follow-up in non-diabetic patients with cardiovascular risks | |
Castano et al. | Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis | |
Pandolfo | Neurologic outcomes in Friedreich ataxia: study of a single-site cohort | |
Yepez et al. | Fibromyalgia and depression: a literature review of their shared aspects | |
Kuo et al. | Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis | |
Krishna et al. | Diagnostic delay and colectomy risk in pediatric ulcerative colitis | |
Luu et al. | Association of severe acute kidney injury with mortality and healthcare utilization following isolated traumatic brain injury | |
Farzanehfar et al. | Sensor measurements can characterize fluctuations and wearing off in Parkinson’s disease and guide therapy to improve motor, non-motor and quality of life scores | |
Febrero et al. | Quality of life, mood and sleep quality in patients with primary hyperparathyroidism. Impact of socio-personal and clinical profile | |
US20190391167A1 (en) | Method for predicting the development of type 2 diabetes | |
US20170161441A1 (en) | Methods and materials for treating pain and depression | |
Li et al. | Pre-existing psychological disorders, diabetes, and pancreatic cancer: A population-based study of 38,952 Finns | |
Gucyetmez et al. | Non-lactate strong ion difference: a clearer picture | |
Nakazato et al. | Plasma taurine is an axonal excitability-translatable biomarker for amyotrophic lateral sclerosis | |
Antsiferov et al. | Selective screening of patients with associated somatic diseases as a method of early detection of acromegaly | |
Guo et al. | Inclusion of frailty improved performance of delirium prediction for elderly patients in the cardiac intensive care unit (D-FRAIL): A prospective derivation and external validation study | |
Laszczyńska et al. | Electronic medical record-based predictive model for acute kidney injury in an acute care hospital | |
Puntis et al. | Specialised early intervention teams (extended time) for first episode psychosis | |
Hökenek et al. | Evaluation of the effect of pancreatic volume on mortality in patients with acute pancreatitis | |
Tasaki et al. | Interpretable deep learning approach for extracting cognitive features from hand-drawn images of intersecting pentagons in older adults | |
Mohammadian-Hafshejani et al. | Risk factors of peripheral neuropathy in patients with type 2 diabetes in Isfahan: Results of a cohort study in Iran | |
Marquis et al. | Clinician-reported outcome (ClinRO) assessments of treatment benefit: Report of the ISPOR clinical outcome assessment emerging good practices task force | |
Badina et al. | The dynamic of changes of pNFH levels in the CSF compared with the motor scales' scores during three years of nusinersen treatment in children with spinal muscular atrophy types 2 and 3. | |
Haehnel et al. | Speech Differences between Multiple System Atrophy and Parkinson's Disease: a Multicenter Study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAFIKOV, RUSLAN;RAFIKOVA, OLGA;REEL/FRAME:060769/0904 Effective date: 20210107 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ARIZONA;REEL/FRAME:061163/0436 Effective date: 20220801 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |